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Abstract
This guidance on the assessment of dermal absorption has been developed to assist notiﬁers, users of
test facilities and Member State authorities on critical aspects related to the setting of dermal
absorption values to be used in risk assessments of active substances in Plant Protection Products
(PPPs). It is based on the ‘scientiﬁc opinion on the science behind the revision of the guidance
document on dermal absorption’ issued in 2011 by the EFSA Panel on Plant Protection Products and
their Residues (PPR). The guidance refers to the EFSA PPR opinion in many instances. In addition, the
ﬁrst version of this guidance, issued in 2012 by the EFSA PPR Panel, has been revised in 2017 on the
basis of new available data on human in vitro dermal absorption for PPPs and wherever clariﬁcations
were needed. Basic details of experimental design, available in the respective test guidelines and
accompanying guidance for the conduct of studies, have not been addressed but recommendations
speciﬁc to performing and interpreting dermal absorption studies with PPPs are given. Issues discussed
include a brief description of the skin and its properties affecting dermal absorption. To facilitate use of
the guidance, ﬂow charts are included. Guidance is also provided, for example, when there are no
data on dermal absorption for the product under evaluation. Elements for a tiered approach are
presented including use of default values, data on closely related products, in vitro studies with human
skin (regarded to provide the best estimate), data from experimental animals (rats) in vitro and
in vivo, and the so called ‘triple pack’ approach. Various elements of study design and reporting that
reduce experimental variation and aid consistent interpretation are presented. A proposal for reporting
data for assessment reports is also provided. The issue of nanoparticles in PPPs is not addressed. Data
from volunteer studies have not been discussed since their use is not allowed in EU for risk assessment
of PPPs.
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Summary
The European Food Safety Authority (EFSA) was asked by the European Commission to assess the
scientiﬁc quality of newly available studies on human in vitro dermal absorption and, based on the
evaluation of the studies, to revise the EFSA PPR Panel guidance on dermal absorption (EFSA PPR
Panel, 2012).
Data on human in vitro dermal absorption for Plant Protection Products (PPPs) were made available
from the European Crop Protection Association (ECPA) and from the Bundesinstitut f€ur
Risikobewertung (BfR) by submitting the study reports and two data sets with extracted information
from the in vitro experiments. A quality check was performed in order to verify if new studies were
conducted according to the current regulatory standards and to identify potential deviations from the
EFSA PPR Panel guidance on dermal absorption. In addition, a plausibility check to validate the
correctness of data entry in the data sets from sources (study reports) was undertaken applying a two
tiers (I and II) validation protocol. The evaluation of the scientiﬁc quality of the new studies described
in the EFSA scientiﬁc report ‘Assessment of new scientiﬁc studies on human in vitro dermal absorption’
(EFSA, 2015) indicated that, although a number of deviations from the application of the EFSA PPR
Panel guidance on dermal absorption have been identiﬁed, the new studies comply with the current
regulatory standards. In the report, it was recommended to analyse the dermal absorption data
applying a model-based statistical protocol and revise the EFSA PPR Panel guidance on dermal
absorption issued in 2012 accordingly (EFSA PPR Panel, 2012).
An updated version of the data sets including individual values was subsequently submitted by
ECPA and BfR. In addition to a two-tiered quality check of submitted study reports (EFSA, 2015), a
plausibility check to verify the correctness of the information available in the updated data sets from
the sources (study reports) conﬁrmed a high quality of data entry. Data analysis provided the scientiﬁc
basis for the revision of the guidance on dermal absorption.
In order to set new default values to be used in the absence of experimental data, two different
statistical modelling approaches are applied to the combined ECPA and BfR data set. In addition,
empirical percentiles are calculated and proposed values for setting default values with quantiﬁed
uncertainties are assessed. Advantages and disadvantages of both empirical and model-based
approaches are also evaluated.
The statistical analysis indicates a signiﬁcant impact on dermal absorption of concentration status
(‘concentrate’ or ‘dilution’) and formulation category, thus new default values for concentrated
pesticide formulations categorised by formulation type and their dilutions are set in the revised
guidance.
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1. Introduction
This guidance is designed to assist notiﬁers, test facilities and Member States’ Authorities on critical
aspects related to the setting of dermal absorption values to be used in risk assessments of
active substances in plant protection products (PPPs) reviewed for approval under Regulation (EC)
No 1107/20091 and Regulation (EU) No 284/20132.
The document is aimed at providing guidance based on the available science in order to improve
consistency of data derivation, presentation and interpretation. Where data are equivocal or lacking,
existing practises and/or recommendations in other regulations/guidance documents are proposed to
be followed since overall, taking into account the uncertainties involved, it is the EFSA PPR Panel’s
opinion that the relevant dermal absorption estimates will be sufﬁciently protective in these cases [see
the scientiﬁc opinion on the science behind the revision of the guidance document on dermal
absorption issued by the EFSA Panel on Plant Protection Products and their Residues (PPR) in 2011].
This document does not address every possible scenario and it is expected that case-by-case
judgement will be needed in some instances. Where case-by-case assessments are necessary, they
should be designed to provide the same level of scientiﬁc rigour as an assessment performed using the
standard principles described in the guidance document, and the evidence and reasoning involved
should be fully documented.
Internationally agreed guidelines exist for the performance of dermal absorption studies in vivo and
in vitro (OECD, 2004a,b; Regulation (EC) No 440/20083). These test guidelines are designed to cover
all types of chemicals and dermal exposure scenarios, not just pesticide formulations. Notably, they
give only minimal guidance on the interpretation of results. This document does not address basic
details of experimental design, which are addressed in the EC test methods B.44 and B.45 [Regulation
(EC) No 440/2008] and in the related OECD test guidelines 427 and 428 (OECD, 2004a,b) and
supporting guidance (OECD, 2004c). It does, however, provide recommendations for performing and
interpreting dermal absorption studies with PPPs in order to reduce variability among studies and to
improve data reliability and interpretation. The potential applicability of this guidance to exposures to
other chemical classes (e.g. biocides or industrial chemicals) will need to be determined by the bodies
responsible for such evaluations.
This guidance also covers scenarios where there are no data on dermal absorption for the product
under evaluation and different types of data are available for either the product under evaluation or
related products or the active substance itself. Flow charts were considered an important part of the
guidance and are therefore included.
The issue of nanoformulations in PPPs is not addressed. Currently, there is insufﬁcient information
on the penetration of nanoparticles through the skin. It is considered that, at present, evaluation of all
aspects of nanoparticle-based PPPs should be performed on a case-by-case basis (WHO, 2006).
In the EFSA PPR Panel ‘Opinion on the science behind the revision of the guidance document on
dermal absorption’ more detailed explanations and rationales for the decision tools presented in the
guidance are provided (EFSA PPR Panel, 2011). Every effort has been made to accurately cross-
reference the relevant sections of the opinion.
Moreover, the EFSA PPR Panel guidance issued in 2012 has been revised in 2017 by the EFSA
Working Group on Dermal Absorption, on the basis of newly available data on human in vitro dermal
absorption for PPPs and wherever further clariﬁcations were needed. Accordingly, Background and
Terms of References have been updated.
1 Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of
plant protection products on the market and repealing Council Directives 79/117/EC and 91/414/EEC. OJ L 309, 24.11.2009,
p. 1–50.
2 Regulation (EU) No 284/2013 of 1 March 2013 setting out the data requirements for plant protection products, in accordance
with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection
products on the market. OJ L 93, 3.4.2013, p. 85–152.
3 Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of
the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals
(REACH). OJ L 142, 31.5.2008, p. 1–739.
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1.1. Background and Terms of Reference as provided by EFSA
1.1.1. Background as provided by EFSA
The preparation and revision of the EU Guidance Documents to assist the implementation of
Council Directive 91/414/EEC was originally the responsibility of the European Commission; this remit
has been transferred to the European Food Safety Authority (EFSA) regarding risk assessment
Guidance Documents. The need for update/revision of the Guidance Document on Dermal Absorption
(SANCO/222/2000 rev.7, 19 March 2004) was expressed by Member States, consulted in 2006. This
message was reinforced in the report from the 2009 public consultation carried out by EFSA on the
Guidance Document, and it was clearly indicated that there was a need for substantial changes.4
In an EFSA outsourced project published in 2010, these comments as well as available databases
on dermal absorption were analysed and relevant literature was reviewed. In the report thereof,
further needs for updates and recommendations for a revised Guidance Document were presented.5
Moreover, the EFSA PPR Panel developed an ‘Opinion on the Science behind the Revision of the
Guidance Document on Dermal Absorption’ (EFSA PPR Panel, 2011), providing relevant data,
evaluations and references that supported the criteria to facilitate assessment of dermal absorption of
active substances in PPPs under Regulation (EC) No 1107/2009.
On this basis, the EFSA PPR Panel was asked by the European Commission to prepare a revision of
the Guidance Document on Dermal Absorption. During the development of the guidance, the EFSA
PPR Panel had a consultation with the Standing Committee on the Food Chain and Animal Health
(SCoFCAH) on risk management issues of the guidance. Among the issues considered were the default
values to be used when data is lacking and the value of 25 w/w content of types of co-formulants
for read across between different formulations. The proposed values were conﬁrmed. Subsequently,
the SCoFCAH took note of the Guidance Document and it entered into force in the European Union
(EU) by December 2012.
In April 2013, the European Crop Protection Association (ECPA) indicated to the European
Commission and to EFSA that the guidance was, in their opinion, excessively conservative and that it
did not take into account new relevant scientiﬁc studies. In particular, ECPA referred to a manuscript
submitted to a scientiﬁc journal for publication in which several amendments to the EFSA PPR
Panel guidance on dermal absorption were proposed (Aggarwal et al., 2014).
EFSA accepted to consider the new data, provided that access to the original study reports
referred to in the scientiﬁc publication was ensured. Agreement was reached with ECPA that
conﬁdentiality about the original study reports would be respected within the limits of Regulation (EC)
No 1049/20016 on EU rules for access to documents. The study reports were submitted to EFSA for
assessment in June 2014.
In September 2014, ECPA indicated that an additional 170 in vitro dermal absorption studies with
human skin conducted during the period 2012–2014 had been added to the existing database of
approximately 190 studies conducted until 2012. The additional studies were submitted to EFSA in
October 2014, together with a draft manuscript (Aggarwal et al., 2015).
After consultation of Members States by the European Commission, Germany informed EFSA that a
structured database containing a large data set on human in vitro dermal absorption had been
compiled by Bundesinstitut f€ur Risikobewertung (BfR). Data have been extracted from original study
reports of PPP submissions and the database includes also rat in vivo/in vitro dermal absorption data.
1.1.2. Terms of Reference as provided by EFSA
The European Commission asks EFSA:
1) To assess in the ﬁrst instance the scientiﬁc quality of all the new studies available and to
compile a comprehensive database of the dermal absorption studies. This should include all
studies in line with the regulatory standards for this type of experiment and made available
by the industry as well as by public institutions.
4 http://www.efsa.europa.eu/en/scdocs/scdoc/282r.htm
5 http://www.efsa.europa.eu/en/scdocs/scdoc/52e.htm
6 Regulation (EC) No 1049/2001 on Access to European Parliament, Council and Commission documents. OJ L 145, 31.5.2001, p.
43–48.
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2) Subsequently, based on the evaluation of the studies, to consider whether the current
guidance on dermal absorption shall be revised or, if more appropriate, a new guidance
developed.
The evaluation of scientiﬁc quality of new studies described in the EFSA scientiﬁc report
‘Assessment of new scientiﬁc studies on human in vitro dermal absorption’ (EFSA, 2015) indicated that,
although a number of deviations from the application of the EFSA PPR Panel guidance on dermal
absorption issued in 2012 have been identiﬁed, the new studies comply with the current regulatory
standards. EFSA’s recommendations to address the variability within studies and to improve the
consistency of interpretation have not been applied routinely. In addition, the data sets as provided to
EFSA were not completed, lacking individual data or other information addressing variability. However,
the overall conclusion regarding the scientiﬁc quality of the provided data sets is that they are uniform
and solid, and include a relevant number of in vitro dermal absorption studies with human skin. In the
report, it was thus recommended to analyse dermal absorption data applying a model-based statistical
protocol and to revise the EFSA PPR Panel guidance on dermal absorption issued in 2012.
An updated version of the data sets including individual values was subsequently submitted by
ECPA and BfR. The quality check to verify the correctness of the information available in the updated
data sets from the sources (study reports) conﬁrmed a high quality of data entry. Data analysis
provided the scientiﬁc basis for the revision of the guidance on dermal absorption
A public consultation and Pesticides Steering Network consultation on the draft guidance on Dermal
Absorption was conducted from 22 December 2016 to 24 February 2017, in order to collect feedback
from stakeholders and provide needed changes to the text, before PPR Panel endorsement, formal
approval by EFSA and publication on the EFSA website.
1.1.3. Interpretation of the Terms of Reference
The EFSA Working Group on Dermal Absorption is asked to prepare a revision of the EFSA PPR
Panel guidance on dermal absorption issued in 2012 on the basis of the evaluation of new human
in vitro dermal absorption studies submitted by ECPA and BfR (EFSA PPR Panel, 2012). Since only
in vitro data on human skin were supplied, considerations involving in vivo data or data on other
animal species cannot be re-evaluated. However, the following data-based considerations present in
the current guidance can be and are reconsidered based on the newly provided data:
• The number of replicates/donors in the experiment and variations (Section 5.3).
• How to deﬁne outliers (Section 5.3)?
• Default values for concentrated and diluted products, based on formulations (Section 6.1).
Both experimental and data interpretation aspects of in vitro dermal absorption described in the
guidance will be updated when the evidence from new data indicates the need for more clarity, such
as for:
• t0.5 calculation (Section 5.1);
• recovery (Section 5.2);
• pro-rata corrections for untested dilutions (Section 5.5);
• exclusion of tape strips (Sections 5.6 and 5.87).
The approach for rounding of values (Section 5.4) will be revised. The section on the use of data
on similar formulations (Section 6.2) will be updated to be in line with regulatory requirements and to
include indications for formulations containing more than one active substance. Whenever needed,
based on changes to the guidance reported above, general Sections 2 and 4, and ﬂow charts
(Section 8) will be updated (e.g. new ﬂow chart 1a for selecting default absorption values, ﬂow
charts 3 and 6). Moreover, the evaluation of possible inconsistencies/deviations among different
guidance/guideline documents on dermal absorption will be conducted to identify possible needs for
harmonisation.
Lastly, considerations on the use of quantitative structure–activity relationships (QSAR) will be
updated to reﬂect recent development in the ﬁeld (Section 6.5.1).
Changes based on the evaluation of new data/information are described under the following
sections:
7 For consistency, respective clariﬁcations were included in the in vivo sections.
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1) Appendix A: Human in vitro dermal absorption data sets: new versions (ECPA and BfR).
2) Appendix B: Statistical analysis.
3) Appendix C: Evaluation of dermal absorption guidance/guideline documents.
4) Appendix D: Evaluation of literature on QSAR for skin absorption prediction.
2. The skin and properties affecting dermal absorption
Below is a summary of relevant information that is presented in the PPR Panel opinion (EFSA PPR
Panel, 2011) and in more detailed reference texts (e.g. Marzulli and Maibach, 1996; WHO, 2006; Zhai
et al., 2008; Dumont et al., 2015).
• The main barrier to absorption of chemicals is the outermost layer of the epidermis, the
stratum corneum, which is typically made of 15–20 layers of non-viable cells.
• The stratum corneum varies in thickness with anatomical site and species (10–600 lm). Hair
follicles and sweat and sebaceous gland density can inﬂuence dermal absorption.
• Human skin is considered to be to be less permeable than that of laboratory animals (WHO,
2006; Monteiro-Riviere, 2008; Holmgaard and Nielsen, 2009).
• Different anatomical sites in humans display a hierarchy of absorption: scrotum > forehead >
torso and arms > palms and soles of feet (EFSA PPR Panel, 2011, section 2.2).
• Dermal absorption studies normally use the back (in vivo studies) or breast/abdomen/back or
upper leg (in vitro studies) that are considered to provide realistic dermal absorption values for
use in exposure modelling (EFSA PPR Panel, 2011, section 2.2).
• Data on the impact of blood ﬂow/vasodilatation are inconsistent (see opinion section 2.3) and
are considered non-relevant variables.
• Sweating and skin hydration have been reported to increase dermal absorption < 2-fold (EFSA
PPR Panel, 2011, section 2.3) and are not considered relevant variables, also because they are
covered by the intra-species variability factors.
• Signiﬁcant skin irritation is not expected to occur in normal settings and hence to enhance
dermal absorption, except when irritants and/or sensitisers are present in the formulation.
However, skin irritation by the active substance and/or by the formulation is already taken into
account from the respective dermal irritation tests. This would not be the case if a formulation
has sensitising potential only (EFSA PPR Panel, 2011, section 2.4).
• The presence of limited areas of damaged skin is not expected to increase the total absorption
(EFSA PPR Panel, 2011, section 2.4).
• The higher permeability (up to twofold) of the skin of an atopic individual is adequately
covered by the safety factors applied to derive the acceptable operator exposure level (AOEL)
(EFSA PPR Panel, 2011, section 2.4.
• Age-dependent differences in skin properties and functions do not require a separate approach
for children and adults when determining absorption values (EFSA PPR Panel, 2011, section
2.5).
• Skin metabolism, although much less active than hepatic metabolism, may affect the kinetics
of absorption and alter the nature of systemically available chemicals (Dumont et al., 2015).
Especially for in vivo methods, it is important to underline the need to cover possible
metabolites or marker compound (or compounds) if non-radiolabelled compounds are used.
However, it is considered that skin metabolism will not alter the total calculated absorption
signiﬁcantly, as the metabolically active cells are below the stratum corneum and the main
barrier to absorption of pesticidal active substances has been passed. In addition, as the
determination of skin absorption for risk assessment considers the total percentage penetration
of a compound into and across the skin, metabolism is not a critical factor in interpreting the
data (EFSA PPR Panel, 2011, section 3.8).
• Properties of the active substance that affect absorption include (EFSA PPR Panel, 2011,
section 2.6):
– octanol/water partition coefﬁcient (log Pow)
– molecular size
– ionisation
Guidance on dermal absorption
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• Other factors affecting absorption (EFSA PPR Panel, 2011, section 2.6):
– solvents
– surfactants
– dilution
– partitioning between solvent and stratum corneum
– particle size (for powders, SC’s, etc.)
– amount of formulation per unit skin area.
Review of available data on pesticide formulations and new human in vitro studies indicates that
(see EFSA PPR Panel, 2011, section 4 and Appendix B):
• octanol/water partition coefﬁcient of the active substance (log Pow) and molecular weight (MW)
alone were not found to be good predictors of absorption of pesticide formulations;
• relative absorption (e.g. expressed as a percentage of the applied dose) is generally inversely
related to the concentration of the active substance. Exceptions may include irritant and
volatile compounds, and the presence of co-formulants that strongly affect absorption;
• formulation type is an important factor for dermal absorption that should be considered in
setting default values for concentrated products and (in use) dilutions to be used in the
absence of data;
• pro-rata correction for untested dilutions is a conservative but appropriate approach in the
absence of data.
Based on these observations and considering the fact that pesticide formulations contain solvents
and surfactants, ideally, dermal absorption data on PPPs should be generated on the formulated
product and on concentrations representative of the spray dilutions as applied to the crop, including
the lowest concentration of the active substance (greatest spray dilution). In case adjuvants are
recommended to be added to the spray dilution, the test item should contain these adjuvants as well
due to an expected impact on dermal absorption.
3. Elements for a tiered approach
Keeping in mind that Regulation (EC) No 1107/2009 and Regulation (EU) No 284/2013 foresee the
use of default values as a ﬁrst tier approach in the absence of data, the assessment of dermal
absorption of PPPs can be performed in a structured manner using the criteria outlined in Section 4.
This will ensure the best use of resources (for notiﬁers, contract laboratories and regulators), including
a signiﬁcant reduction in the use of animals, and provide the highest level of conﬁdence in the
outcome. Before conducting any studies involving experimental animals, exposure assessments should
be performed using default values or existing relevant information, including those from in vitro studies
(see Section 6, ﬂow charts 1a, 1b and 2).
Below is a list of studies and approaches that can be used in the suggested tiered approach (ﬂow
charts 1a, 1b and 2), taking into account that scientiﬁcally sound human volunteer in vivo data, even if
ethically performed, cannot be used for PPPs in the EU.8
The following list reﬂects different levels of reﬁnement:
• Default values or data on closely related products can be used in an initial exposure
assessment (see Sections 6.1 and 6.2).
• In vitro studies using human skin should be performed before testing in animals is considered.
• Existing data on rats (or other experimental animals): It is widely accepted that results from
animal models will over-predict human dermal absorption. Therefore, if animal data from more
than one well-designed and well-performed study are available (either in vitro or in vivo), it is
justiﬁed to use the lower dermal absorption value.
• ‘Triple pack’ approach: Existing in vivo data in rats (or other experimental animals) are
corrected for the ratio of absorption between rats and humans in vitro. It should be noted that
this will not necessarily provide a value lower than the human in vitro data alone (see
Section 5.9, ﬂow chart 2 and EFSA PPR Panel, 2011, section 5.4). Rat data generally
overpredict dermal absorption, and therefore, it is justiﬁed to take the lower value from human
in vitro data in case this occurs.
8 Regulation (EC) No 1107/2009.
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4. Elements of a study design and reportings that reduce experimental
variation and aid consistent interpretation
In order to improve consistency of interpretation of in vivo and in vitro study data, it is important
that the study protocols are standardised. The EC test methods B.44 and B.45 are designed to cover
all types of chemicals and therefore provide a high level of ﬂexibility. This ﬂexibility can lead to a wide
variation in designs for dermal absorption studies on PPPs and hence variability in how the studies are
interpreted. It is therefore proposed that any dermal absorption studies on PPPs are performed
according to EC test methods B.44 and B.45, but with additional considerations:
1) Tests should use the formulated product being considered for authorisation.
• (If not, it may be possible to extrapolate between similar formulations – see Section 6.2)
2) In addition to the concentrated product, the greatest dilution (lowest concentration) of the
product recommended for use should be tested. If a wide range of dilutions is proposed,
then more than one dilution should be tested so that the greatest and smallest
recommended dilution rates are covered.
• (If the greatest dilution recommended on the label has not been tested, the pro rata
correction can be made from the highest dilution tested; see Section 5.5 for further details.)
3) In vitro studies with human skin should preferably use split-thickness (200–400 lm)
(dermatomed) skin and be from the abdomen, back, breast or upper leg. This is to improve
consistency and comparability particularly as split-thickness membranes tend to have
signiﬁcantly lower levels of residual material than full-thickness preparations (OECD, 2004c;
WHO, 2006; Wilkinson et al., 2006; see EFSA PPR Panel, 2011, section 3.1). The use of
epidermal membranes may, in some cases, overestimate human in vivo skin absorption
because of insufﬁcient barrier function (see EFSA PPR Panel, 2011, section 3.1). The use of
cultured and reconstructed human skin models (e.g. constructed from keratinocytes) is not
recommended for the determination of dermal penetration as these models have not been
validated for dermal absorption studies and there are reports that their barrier function is
not comparable with that of skin of ‘natural origin’ (WHO, 2006; SCCS, 2010).
• (If full-thickness skin is used, the main difference from split-thickness skin is in the
amount of material in the receptor ﬂuid and the ﬂux, with the sum of receptor ﬂuid plus
skin sample being similar for both split-skin and full-thickness samples (Wilkinson et al.,
2006; Vallet et al., 2007). Therefore, by including all material remaining in the skin
sample, a dermal absorption value can be obtained. However, any calculated ﬂuxes
should not be used).
4) In vitro studies with rat skin should preferably use split-thickness (200–400 lm) skin from
the abdomen or back.
• (If not, see point 3 above.)
The integrity of human or rat skin used in vitro should be determined prior to application of the test
substance and should be documented. Various methods can be used (e.g. transepidermal resistance,
transepidermal water loss or reference substance penetration) (see OECD, 2004c, para. 42–46). Any
membrane with unacceptable integrity should be replaced prior to application. Post-dosing evaluation
of integrity instead of predosing evaluation, and subsequent exclusion of results obtained with skin
having insufﬁcient integrity is not recommended.
5) Solid material should be moistened with a minimal volume of vehicle (e.g. water or
physiological saline) to make a paste. This is to mimic sweat on the skin or occlusive
conditions under clothing. Since dermal exposure to granular products is usually in the form
of dust, the granules should be ground and moistened before application to the skin.
Organic solvents should not normally be used (see EFSA PPR Panel, 2011, section 3.2.)
• (If solids are not moistened then the validity of the study is questionable. If solids are
not moistened but occlusive conditions are used then the study can be considered a
reasonable match to actual exposures, except for granules.)
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6) After tape stripping, strips should be analysed separately to permit a proﬁle of the residual
material to be determined (for further details see Section 5.1 and EFSA PPR Panel, 2011,
section 3.6). Glued (e.g. cyanoacrylate superglue) tape strips should not be used.
• (If tape strips are not reported individually, then it is not possible to determine whether
or not the residue is at the surface or in the lower layers. In such cases, the tape strips
should be considered as being part of the material in the skin sample/application site; if
glue is used, the complete stratum corneum is removed by 1–2 strips; hence, the
complete amount in the stratum corneum should be considered as potentially absorbed.)
7) As a minimum requirement, results from at least four replicates should be analysed in
in vitro studies in line with the recommendations given in EC test guideline B.44 (in vivo
dermal absorption). For statistical reasons, a larger number of replicates is preferred. SCCS
(2010) recommends eight evaluable samples originating from four donors. The PPR
Panel recommends for new studies to follow this approach for PPPs as well, particularly
since animal welfare is not an issue for human skin samples.
• (If less than four acceptable replicates are available, additional experimental data should
be generated or one should revert to default values.)
8) Solubility of the test compound in the receptor ﬂuid must be demonstrated as not being a
rate limiting factor and should be at least 10 times higher than the expected (maximum)
concentration of the test compound in the receptor ﬂuid at the end of an in vitro study (see
EFSA PPR Panel, 2011, section 3.3). Note that although conﬁrming solubility in the receptor
ﬂuid is a requirement in EC test method B.45, it is often not reported.
• (If test compound solubility in the receptor ﬂuid is less than 10 times higher than its
expected (maximum) concentration in the receptor ﬂuid at the end of an in vitro study,
the validity of the study is questionable.)
9) Exposure should mimic a working day (e.g. 6–10 h) with sampling for at least 24 h in vitro
and a minimum of 96 h in vivo (see EFSA PPR Panel, 2011, section 3.5).
• (If the exposure period is shorter, this can be compared with the lag-phase. If the
product is removed before the end of the lag-phase is reached, the relevance of the
study is in doubt. If the product is removed after the lag-phase is completed, it is
possible to make a pro rata correction for the shorter duration, based on results of the
linear phase. If sampling does not continue for an adequate period, all material in the
skin sample/at the application site should be included in the determination of the dermal
absorption value, or, if possible, absorption should be determined by extrapolating to an
adequate time point.)
10) After the end of experimental exposure, the skin is washed and the characteristics of the
skin rinsing step should be indicated in the report. The cleansing agent should be
representative of normal hygiene practices (e.g. an aqueous soap solution).
• (If washing is not performed, an overestimate of the absorption is likely to occur.)
11) When performing studies designed to permit correction of rat in vivo data with rat and
human in vitro data, the in vitro and in vivo data should be as closely matched as possible
in terms of rat strain used, exposure time, tested material, skin sample preparation, state of
occlusion, vehicle, solvent/formulation volume per unit area and dilution rates/amount of a.i.
per unit area (see Section 5.9 for details).
• (If the rat and human in vitro studies and rat in vivo studies are not comparable, the
human in vitro value can still be used on its own.)
12) Data should be presented for individual animals/replicates and as group means  standard
deviations.
13) Maximum ﬂux should be based on the calculation of the slope of the linear portion of the
absorption: time curve and should not include the lag-phase or plateau.
14) If overall recovery is consistently low (mean over all animals or replicates < 95% for
radiolabelled studies), this does not necessarily mean that the study cannot be accepted but
an explanation must be provided as to why the missing material should not be considered
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as absorbed. However, if the calculated dermal absorption value is < 5% and recovery
< 95%, the missing amount should be added to the observed amount.
• [For rules on how to proceed when recovery (mass balance) is low (< 95%), see
Section 5.2.]
15) To address variability between replicates, a multiple of the standard deviation should be
added to the mean dermal absorption value (see Section 5.3).
• (If there is signiﬁcant variation between replicates, see Section 5.3 for details.)
16) If non-radiolabelled material is used, the analytical methods used to determine the amount
of absorbed material must be able to account for metabolism and hydrolysis, or data must
be presented to permit back calculation from the analysed components to the amount of
active substance absorbed (see Section 6.3 for details).
• (For non-radiolabelled studies, if the relationship between the recovered material and
the amount absorbed cannot be demonstrated, a conservative default could be to
assume that any deﬁcit in the mass balance is absorbed material.)
5. Interpretation of studies
5.1. Tape stripping
See EFSA PPR Panel (2011), sections 3.4, 3.5 and 3.6.
Tape stripping is a procedure performed at the end of a dermal absorption study that involves the
sequential application of adhesive tape to the area of skin that was exposed to a chemical (Trebilcock
et al., 1994). If the tape strips are analysed individually, a proﬁle of the chemical across the stratum
corneum can be determined.
There has been a general practice within EFSA PRAPeR9 meetings to assume that the ﬁrst 2 tape
strips will represent material that will not become bioavailable due to desquamation. The PPR
Panel proposes to follow this approach, that applies to both in vitro and in vivo studies (see EFSA PPR
Panel, 2011, section 3.6).
Only if permeation (in vitro) or absorption (in vitro) is essentially complete at the end of the study,
usually after a 24-h sampling period, can all tape stripped material be excluded from calculation of the
absorbable dose fraction [see Section 5.6 option (i)]. This applies to both in vitro and in vivo studies
(see Sections 5.5 and 5.7, and see EFSA PPR Panel, 2011, sections 3.4 and 3.5 providing the
background for this statement).
For in vitro studies, permeation is considered essentially complete when > 75% of the amount that
has permeated into the receptor ﬂuid at the end of sampling (usually at 24 h) has reached the
receptor ﬂuid at the half time of the sampling period (usually at 12 h). For an in vitro study with a
sampling period of 24 h, the mean relative permeation into the receptor ﬂuid occurring within half of
the sampling period (t0.5) should be calculated from the individual replicate data on amounts
recovered in receptor ﬂuid (RF) at 12 h (RF12) and 24 h (RF24) as follows:
t0:5 ¼ 100%
Xn
i¼1
RF12i
RF24i
 1
n
n= number of valid replicates
If the t0.5 value is close to 75%, a conﬁdence interval should be estimated to demonstrate
credibility of the conclusion that permeation is essentially complete. This can be achieved in analogy to
the approach described in Section 5.4: a standard deviation is calculated from individual RF12i/RF24i
ratios and multiplied by the k-value taken from Table 1. The lower limit of the 95% conﬁdence interval
is approximated as t0.5 (mean value) – ks, where s is the sample standard deviation. For in vivo
studies where there is evidence that absorption is nearing completion, where less than 75% is
absorbed (as described in Section 5.8), material from all tape strips can be excluded from the
absorbed material if the evidence indicates that it is not bioavailable. However, this should be critically
assessed on a case-by-case basis.
9 Peer Review of Pesticide Risk Assessment (carried out under the responsibility of EFSA’s Pesticide Unit in the EU).
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For both in vitro and in vivo studies, recovery for replicates and animals should be within the set
limit (see section 5.2).
A template (Excel ﬁle) to support calculations (including t0.5) for dermal absorption from in vitro
studies has been provided by BfR and published as supporting information. The Working Group (WG)
conﬁrms the template is in line with the requirements in the EFSA guidance and recommends using
the template as part of the dossier.
5.2. Recovery
When recovery is below the set limit (mean over all animals/replicates < 95%), there is a need to
consider whether the missing material should be considered as absorbed. It should be noted that the
average should be calculated based on the recoveries determined for each individual animal/replicate.
This also allows reporting a standard deviation for recovery, providing an indication for variability
across replicates. The recovery value of 95% is stricter than that in the OECD test guidelines, but with
modern analytical and pipetting techniques it is regularly achieved. A high level of recovery is required
to support a low dermal absorption value; for example, if 9% of the test material is unaccounted for
there is a high degree of uncertainty surrounding a proposed dermal absorption value of 1%. In such
cases, additional evidence needs to be supplied to identify which element of the assay is associated
with the missing material and that it is not speciﬁcally associated with material used in the calculation
of absorption.
1) If overall recovery is consistently low (mean over all animals/replicates < 95% for
radiolabeled studies), as a worst-case assumption, the missing material should be
considered as absorbed and added to the absorbed amount, unless it can be justiﬁed that
the missing material is unlikely to have been absorbed. Adding the missing material should
certainly apply when the calculated dermal absorption value is < 5% and recovery is
< 95%.
2) Alternatively, a ‘normalisation’ approach could be applied in which dermal absorption is
expressed as a percentage of the total amount recovered (except when the calculated not-
normalised dermal absorption is < 5%, then the addition rule stands). Values for all
animals/replicates should be normalised individually. However, in principle, normalisation is
the preferred option, critical evaluation of the available data needs to be performed to
determine if signiﬁcant amounts of the missing material could have been absorbed (e.g.
from in vivo studies exhaled as CO2). In such a situation, no normalisation is recommended,
and consequently, the missing amount should be added to the absorbed amount.
3) If there are some replicates/animals with adequate recoveries, then the results for low and
high recovery animals/replicates can be compared to those with adequate recovery to see if
the losses are from absorbed or non-absorbed material.
Losses that are considered to be from non-absorbed material will have no impact on the results.
If losses appear to be from absorbed material, the values should be corrected for the losses by
considering the lost fraction as absorbed.
If no clear conclusion can be drawn, only values from high recovery samples should be used to
derive the absorption and replicates with low recoveries should be excluded entirely. However, as
exclusion reduces the overall number of replicates, a balance must be found between uncertainty
resulting from low recoveries and uncertainty from a lower number of acceptable replicates.
Low recovery (mean over all animals/replicates < 95%) is less of an issue when there is a high level
of absorption as the impact will be proportionally lower. For volatile or potentially volatile compounds,
measures should be taken to prevent loss (e.g. charcoal ﬁlter occlusion to achieve acceptable recovery
despite volatilisation, see also Section 5.8).
5.3. Variability within the results and outliers
The preferred approach to addressing variability between replicates/animals is to add a multiple of
the standard deviation to the mean value. The multiplication factor required depends on the number
of replicates and is given in Table 1. The standard deviation of the absorption value should be
calculated as indicated in Section 5.6 and the mean absorption as deﬁned in Sections 5.6 and 5.8. The
result of this calculation approximates the upper limit of the 95% conﬁdence interval for the mean
absorption (see Appendix B for the statistical justiﬁcation). The use of the upper conﬁdence limit
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addresses uncertainty about mean absorption due to sampling variability. This approach is reasonably
conservative and could reduce the need to repeat studies (particularly in vivo studies).
Thus, to address variability between replicates/animals, dermal absorption should be calculated as
follows: Absorption (mean value) + ks, where s is the sample standard deviation.
Clear statistical criteria to deﬁne outliers to be considered for removal should be provided in the study
report, taking into account the tendency of absorption data to be skewed. However, outliers should not
be removed on statistical grounds alone; a plausible cause for the value being an outlier should be put
forward, e.g. a membrane damaged during the experiment. If not, it should be considered part of
normal experimental variation and not be left out. Once a replicate has been excluded based on an
outlying parameter value, it should be excluded from calculations for all other parameters as well.
Reasons for excluding outliers should be clearly stated in the study report and summary text. In
addition, the full results from the samples considered to be outliers must be presented. It should be
noted that results treated as outliers should include spuriously low values as well as high ones.
5.4. Rounding of values
Dermal absorption studies tend to have a relatively high level of variability associated with the
results. So as not to imply spurious precision, ﬁnal dermal absorption (i.e. after pro-rata or triple pack
corrections) values should be rounded to a maximum two signiﬁcant ﬁgures.
For example:
0.098% = 0.098%
0.268% = 0.27%
1.839% = 1.8%
14.86% = 15%
56.77% = 57%
85.22% = 85%
5.5. Dilution rates (tested concentrations)
See ﬂow chart 3.
The concentration(s) tested should cover the extremes of those recommended on the product
label. If the lowest concentration tested is greater than the lowest concentration of the same
formulation recommended on the label, consideration should be given to increasing the dermal
absorption pro rata to account for any limitation of absorption due to the amount of material applied
to the test site. However, if the dermal absorption from the concentrate, a dilution and the lowest
tested concentration (second dilution) shows no indication of concentration related absorption, then
there is no need to increase the value for the lower (untested) concentration of the same formulation
recommended on the label.
Table 1: Approach for the treatment of variability within the results
Number of replicates (n) Multiplication factor (k)
4 1.6
5 1.2
6 1.0
7 0.92
8 0.84
9 0.77
10 0.72
11 0.67
12 0.64
13 0.60
14 0.58
15 0.55
16 0.53
Values of k were calculated assuming an underlying normal distribution as an approximation for variability and random sampling.
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Pro-rata correction assuming a proportional response is considered to be a conservative but
appropriate approach in the absence of data and is a concept of worst-case linear extrapolation which
applies to dilutions (see also Appendix B).
In case the same formulation and its dilution(s) are tested, this approach can be used to derive
dermal absorption values for other dilutions with concentrations of the same formulation lower than
the highest dilution (lowest tested active substance concentration). The linearity is assumed from the
origin (0,0) to the highest dilution (lowest tested active substance concentration). Pro-rata correction
should not be used to derive dermal absorption values for dilutions with higher concentrations (e.g.
extrapolation back from a dilution towards the concentrate or from a dilution towards a less diluted
formulation). In that case, the dermal absorption from the tested dilution should apply (the closest
experimental tested dilution). It should be noted that if the pro rata correction gives a value above the
default value for dilutions (see Section 6), then the respective default value should apply.
The following example is presented to clarify some of the conditions to be fulﬁlled:
Default approach – difference between dilutions
Dermal absorption of 1 + 50 dilution = 12%.
Highest label dilution is 1 + 80 for which a value of 12 9 80/50 = 19% can be derived using the
pro-rata correction.
Correction necessary.
Reﬁnement of the default approach is possible if it is demonstrated, e.g. that there is no change of
dermal absorption within the relevant dilution/concentration ranges. The corresponding justiﬁcation
should address at least the following points:
• data justifying such a conclusion;
• statistical uncertainty in measured values on which the conclusion is based.
5.6. In vitro studies10
Flow chart 4a, see EFSA PPR Panel (2011), section 3.1.
Human skin samples provide the best estimate of dermal absorption. If non-human skin is used,
then the rat would be recommended for consistency reasons. If a dermal absorption study with rat or
human skin samples has been well performed (see Section 4 and EC test method B.45), the dermal
absorption should be calculated on the following basis using mean values:
i) when:
• the sampling period is 24 h
and
• it can be concluded with conﬁdence that over 75% of the permeation (to be calculated as
described in Section 5.1) occurred within half of the duration of the total sampling period
Absorption = receptor ﬂuid + receptor chamber washes + skin sample (excluding all tape strips)
ii) when:
• the sampling period is less than 24 h
or
• less than 75% of the absorption occurs within half the duration of the study
then
Absorption = receptor ﬂuid + receptor chamber washes + skin sample (excluding tape strips 1 and 2)
If tape stripping has been performed with strips being pooled, then all tape strips should be
included in the absorbed material.
When calculating means and standard deviations for the absorption values, absorption should be
calculated for each individual replicate, and the average and standard deviations should be determined
using these absorption values for individual replicates.
10 Use of reconstituted skin is not recommended, see Section 4.
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To address variability between replicates, a multiple of the standard deviation should be added to
the mean dermal absorption value (see Section 5.3).
A template (Excel ﬁle) to support calculations for dermal absorption from in vitro studies has been
provided by BfR and published as supporting information. The WG conﬁrms the template is in line with
the requirements in the EFSA guidance and recommends using the template as part of the dossier.
5.7. Non-human primates in vivo
Flow chart 4b, see EFSA PPR Panel (2011), section 3.9.
The use of non-human primates is not recommended; however, the following guidance is provided
for the evaluation of existing studies.
In order to use in vivo data on non-human primates the following points need to be addressed:
• A minimum group size of 4 should be used (this is in line with EC test method B.44). If smaller
numbers are used, then the highest result, rather than the mean, should be chosen.
• The application site should be one that gives a realistic level of dermal penetration (e.g.
forearm, torso, forehead). Correction for mass balance needs to be done if non-human
primates were not sacriﬁced at the end of the study and non-radiolabelled material was used.
• The analyses need to cover possible metabolites or use a marker compound(s) that can be
back extrapolated to absorbed material based on the amount in urine, faeces and exhaled air.
• It is not usually possible to determine the residue in the dermis at the application site or
distributed within the body.
• Compare the excreted material following oral or intravenous and dermal dosing. The dermal
study should include a long enough sampling duration to conﬁrm that excretion is essentially
complete. For example, if 25% of an intravenous dose is detected in excreta using a particular
analytical technique and 5% of a dermal dose is detected in excreta then the dermal
absorption can be considered to be 20% (5% 9 100/25).
• Exclude an extensive ﬁrst pass metabolism, incomplete absorption or extensive biliary
excretion. A ﬁrst tier approach would be to assume 100% oral absorption, and determine the
ratio of the amount detected in urine in the dermal study with the amount in urine from the
oral study.
• Take blood samples and determine the ratio of the area under the curve (AUC) from
intravenous or oral dosing with that from an equivalent dermal dose. The default assumption is
100% absorption from the oral route: e.g. (AUC dermal/AUC oral) 9 100 = % dermal
absorption.
It is the responsibility of the notiﬁer to present a justiﬁcation for the analytical method used and
how the recovered material relates to the amount actually absorbed. Alternatively, as a conservative
approach, all material not recovered in the skin washes plus the ﬁrst two tape strips (if performed) can
be considered as absorbed.
5.8. Rat11 in vivo
Flow chart 4b, see EFSA PPR Panel (2011), section 3.4.
If a dermal absorption study in rats has been well performed [see OECD test guideline 427 (OECD,
2004a)], the dermal absorption should be calculated on the following basis using data from the
terminal sampling time:
i) When:
• the sampling period is 24 h or longer
and
• it can be concluded with conﬁdence that over 75% of the total absorption (material in
excreta, exhaled gasses and in the carcass at the end of the study) occurred within half of
the duration of the total sampling period (may be evaluated in analogy to the approach
described in Section 5.1 for in vitro studies)
then
Absorption = excreta + CO2/volatiles (in exhaled air) + carcass + skin (excluding tape strips)
11 Rat or any other non-primate experimental animal.
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ii) When:
• the sampling period is less than 24 h
or
• less than 75% of the absorption (as described above) occurs within half the duration of
the study
then
Absorption = excreta + CO2/volatiles (in exhaled air) + carcass + skin (excluding tape strips 1 and 2)
To address variability between replicates/animals, a multiple of the standard deviation should be
added to the mean dermal absorption value (see Section 5.3).
If tape stripping has been performed with strips being pooled, then all tape strips should be
included in the absorbed material.
iii) In cases where the evidence indicates that absorption was essentially complete at the end of
the study (e.g. marked decline in the amount over the last three sampling times), but the
criteria in option (i) above were not met, a case-by-case consideration of the potential
bioavailability of the application site residue can be made. This should take account of factors
such as whether the remaining material is in the outer layers of the stratum corneum and the
duration of the study. For example, if the study was run for only 96 h and the majority of
the residual material is in tape strips from the lower layers of the stratum corneum, then the
material is probably bioavailable. If the study was run for 168 h and the majority of the
material is in the tape strips from the upper layers of the stratum corneum, it is reasonable to
exclude these tape strips.
iv) Poor recovery in in vivo studies can be due to a variety of reasons that can be investigated
further using data normally available.
• If the exhaled volatiles have not been measured and the radiolabel is on a part of the
molecule that could be cleaved and give rise to CO2 and/or exhaled volatiles, it is
reasonable to assume that some or all of the missing material was absorbed and lost via
exhalation. Some information on exhaled volatiles/CO2 is often available from the oral
absorption, distribution, metabolism and excretion (ADME) data (assuming the same
radiolabel position is used). If no volatiles or CO2 were detected in the oral ADME study, it
is reasonable to conclude that this route will not be the reason for poor recovery following
dermal exposure.
• Desquamation might be a cause of poor recovery particularly if the duration of the study is
7 days or longer. If a signiﬁcant amount of material is removed by the ﬁnal swabbing and/
or is present in the ﬁrst tape strip, this could support an argument that the poor recovery
is due to desquamation and the missing material was not absorbed. On the contrary, if
there is only a small amount of material obtained with the ﬁnal swabbing or the ﬁrst tape
strip, it is unlikely that desquamation would have been a cause of signiﬁcant loss.
In all cases of poor recovery (mean < 95%), reasoning why the missing material should not be
considered as absorbed, has to be presented (see Section 5.2).
5.9. Integration of in vivo and in vitro data
See EFSA PPR Panel (2011), section 5.4.
To ensure scientiﬁc validity, it is essential that the study protocols for the human and rat skin
in vitro studies are well matched for variables that could inﬂuence the results, for example:
• Skin type (i.e. split-thickness)
• Test material/formulation/vehicle/concentration/amount per unit skin area of the active
substance
• State of occlusion, exposure duration and sampling period
• Receptor ﬂuid composition
• Swabbing technique
• Analytical techniques
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Also, the results should meet the quality criteria set above, in particular with respect to variability,
number of acceptable replicates and recovery (see Sections 5.2 and 5.3).
In the in vivo study, the same test material/formulation/vehicle/area dose (concentration) and a
similar exposure time and swabbing technique should be used as in the in vitro studies.
Normally, this will be achieved by performing the studies contemporaneously at the same test
facility; however, this is not an essential requirement. If the human and rat skin in vitro studies are not
well matched, then the possibility of a comparison of the relative dermal absorptions should be very
carefully evaluated.
If the in vitro studies are closely matched to each other and to the in vivo study, the in vivo human
dermal absorption can be derived based on the following equation:
In vivo human absorption = [(in vivo rat absorption) 9 (in vitro human absorption)] / (in vitro rat
absorption).
The calculation can be based on either % absorption (option 1) or ﬂux (option 2).
Option 1:
• Calculate % absorption.
• The relative absorption can be estimated by taking the ratios of the % absorption.
Then, the derived human in vivo value will be:
in vivo human%absorption ¼ in vivo rat%absorption
in vitro rat%absorption
 in vitro human%absorption
Option 2:
• Calculate the maximum ﬂux, normally from a linear portion, of 2 h or longer, of the absorption-
time curve. A shorter time period may be used if absorption is very rapid and essentially
complete within 4 h.
• The relative absorption can be estimated by taking the ratios of the maximum ﬂux.
Then, the derived human in vivo value will be:
in vivo human%absorption ¼ in vitro human flux rate
in vitro rat flux rate
 in vivo rat%absorption
There are circumstances when the ﬂux might not be appropriate (e.g. the linear phase is
signiﬁcantly longer in the human samples). In these cases, the comparison can be performed using
the % absorbed, but it must have the same basis for both rat and human samples (i.e. in terms of
inclusion of tape strip material or residue in the skin sample).
A template (Excel ﬁle) to support calculations for dermal absorption from in vitro studies has been
provided by BfR and published as supporting information. The WG conﬁrms the template is in line with
the requirements in the EFSA guidance and recommends using the template as part of the dossier.
5.10. Choice of dermal absorption values for worker/resident exposure
Until the outcome of the ongoing research into this aspect is available and conclusions have been
drawn, it is proposed that the appropriate dermal absorption value for exposures to dried dispersed
residue should be the higher of the values for the concentrate and the in-use dilution.
If an acceptable estimate of worker/resident exposure cannot be obtained using this approach,
speciﬁc evaluations could be performed on a case-by-case basis. These could take into account factors
such as the level of the dislodgeable foliar residue (mass/unit area) and transfer coefﬁcient vs the
loading used in the dermal absorption studies with concentrate and dilution(s) to help determine the
most appropriate dermal absorption value to use. Any lowering of default values commonly applied in
exposure models should be justiﬁed.
5.11. Use of data from ﬁeld studies
Dermal absorption estimated in ﬁeld monitoring studies of workers/operators is rarely accurate
because of difﬁculties in measuring skin deposition and of knowing metabolism in humans. Therefore,
data obtained in these studies can only be used to support experimentally determined values.
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6. How to proceed when there are no data on the formulation under
consideration
This approach is outlined in ﬂow chart 1a. When using it, care should be taken to ensure that the
outcome is relevant for the product under consideration.
6.1. Default values
Based on the evaluation of new human in vitro data, indicating a signiﬁcant impact on dermal
absorption of concentration status (‘concentrate’ or ‘dilution’) and formulation category, the following
default values are recommended (see Table 2; Appendices A and B for details).
A default dermal absorption value of 25% may be applied for concentrated products that are
organic solvent-formulated(a) or in other(b) types of formulations.
A default dermal absorption value of 10% may be applied for concentrated products that are
water-based/dispersed(c) or solid-formulated(d).
A default dermal absorption value of 70% may be applied for (in use) dilutions of organic solvent-
formulated(a) or in other(b) types of formulations.
A default dermal absorption value of 50% may be applied for (in use) dilutions water-based/
dispersed(c) or solid-formulated(d).
The grouping of formulation types into categories used for the statistical estimates intended to
support the setting of default values (see Table B.2 presented in Appendix B) is based on information
on the chemical composition of the tested product, information on the phase in which the active
substance is dissolved or emulsiﬁed/suspended and the expectable impact on dermal absorption. To
select the appropriate default, the ‘Manual on development and use of FAO and WHO speciﬁcations
for pesticides’ should be used for categorisation of formulations to select the appropriate default
(FAO/WHO, 2016).
The categorised groups were organic solvent-based, water-based/dispersed, solids and other
formulation types. Default values are set for concentrated products12 and for their (in use) dilutions
(see above). If special formulation types are not contained in the data set and cannot be grouped with
the proposed categories the worst-case default values should be adopted (solvent based + other).
Ready-to-use products have to be categorised as well. A ready-to-use product might be a dilution of a
concentrated product sold in a smaller packaging for non-professional users. In this case, it is
reasonable to categorise this product as a dilution of the respective concentrated formulation. Gel baits
or slug pellets, for example, should be categorised as ‘other’ because these are ready for use (RB)
formulations and the compositions are clearly different from solid formulations.
6.1.1. Consideration of the oral absorption value when setting a default value
Flow chart 1b, see EFSA PPR Panel (2011), section 5.1.
Table 2: Default values to be used in the absence of experimental data
Formulation category Concentration status Default value
Organic solvent-based(a) or other(b) Concentrate 25%
Dilution 70%
Water-based/dispersed(c) or solid(d) Concentrate 10%
Dilution 50%
(a): Formulation types: emulsiﬁable concentrate (EC), emulsion, oil in water (EW), suspo-emulsion (SE), dispersible concentrate
(DC), oil miscible liquids (OL/OF), oil-based suspension concentrates (OD), emulsion for seed treatment (ES), microemulsion
(ME).
(b): Formulation types: bait concentrate (CB), capsule suspension (CS), gel for direct application (GEL/GD), bait, ready for use
(RB), mixture of capsule suspension and suspension concentrate (ZC), seed coated with a pesticide (PS), experimental
solution of active substances in solvent (AI).
(c): Formulation types: soluble concentrate (SL), suspension concentrate (SC), ﬂowable concentrate for seed treatment (FS),
ﬂowable (FL) (=SC).
(d): Formulation types: wettable powder (WP), water-dispersible granules (WG/WDG), water-soluble granules (SG), water-soluble
powder (SP), powder for dry seed treatment (DS).
12 Products as placed on the market.
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In exceptional cases, if oral absorption is less than 70% for organic solvent-based or other
formulations or less than 50% for water-based/dispersed or solid formulations, this can be used as a
surrogate dermal absorption value for (in-use) dilutions. If oral absorption is less than 25% for organic
solvent-based or other formulations or less than 10% for water-based/dispersed or solid formulations,
it can be used instead of the default value for concentrated products. There are usually no oral ADME
studies for formulations that include co-formulants which are possibly modifying dermal absorption. For
these reasons, estimates based on oral absorption should be applicable in only a limited range of
circumstances after careful consideration of doses and vehicle used in the ADME studies, where
bile-cannulation was also performed.
6.2. Use of data on similar formulations
Flow chart 5, see EFSA PPR Panel (2011), sections 2.6 and 4.4.
Dermal absorption data on another (reference) formulation can be used if the formulation for which
dermal absorption needs to be determined is closely related. This occurs when all the following
conditions are met:
• Content of relevant components in the formulation to be assessed (e.g. other active substance,
synergist, safener, wetting agent, surfactant, solvent, emulsiﬁer, preservative, stabiliser, detergent,
adhesive, antifreezing substance (= all co-formulants), similar chemical types of co-formulants
might be grouped as described below) is within permitted variation ranges of those in the reference
formulation. The permitted ranges are provided in Table 3. The given concentration ranges and
permitted variations are based on the bridging principles for hazard assessment of mixtures
provided by the Regulation (EC) No 1272/200813 and the guidance on signiﬁcant and non-
signiﬁcant changes (Sanco/12638/2011, 20 November 2012 rev.2), respectively.
Addition of substances not contained in the reference formulation might be acceptable up to a
concentration of ≤ 0.5%, but only if it is shown or scientiﬁcally justiﬁed that this minor change does
not have an impact on physical–chemical or toxicological properties of the formulation. In individual
cases, greater variations might be acceptable, for example, replacement of a co-formulant by water
or increase of an inert compound.
• Co-formulants of both formulations are chemically and physicochemically closely related (e.g.
toluene vs xylene; octanol vs nonanol; e.g. linear alkyl sulfonate is not replaced by an aromatic
sulfonate derivative) as well as with respect to interaction with the active substance (e.g.
solubility or enhancement of toxicological properties). However, the evaluation of similarity
should be expert judgement on a case by case basis.
• Additional active substances do not possess properties that may change skin permeability (e.g.
irritant and sensitising properties).
• Formulation is of the same or lower skin irritancy based on scores in studies. These must
include initial ﬁndings (as dermal absorption is often signiﬁcant within the ﬁrst 24 h), not just
the classiﬁcation. If no skin irritation study is available, a comparison based on the irritancy of
the components can be performed, but the outcome should be interpreted with care as
classiﬁcation does not take initial irritation scores into account.
Table 3: Permitted variation for similar formulation
Initial concentration range of the
constituent (% w/w)
Permitted (relative) variation (%)
≤ 0.5 100
≤ 1.0 50
≤ 2.5 30
2.5 < c ≤ 10 20
10 < c ≤ 25 10
25 < c ≤ 100 5
c: concentration.
13 Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classiﬁcation, labelling
and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending
Regulation (EC) No 1907/2006. OJ L 353, 31.12.2008, p. 1–1355.
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• Formulation having the same or no sensitising potential based on classiﬁcation.
• Active substance concentration is within permitted variations of that in the reference
formulation as given in Table 4, based on the FAO and WHO speciﬁcations for pesticides
(FAO/WHO, 2016, chapter 4.3.2)14
• If it is demonstrated that the percentage dermal absorption is inversely related to the
concentration of the active substance, a dermal absorption value of a lower concentrated
formulation (dilution) could apply to formulations containing higher amounts of the active
substance if the other conditions are fulﬁlled.
It is considered unlikely that the above criteria will be met when moving from one formulation type
to another (e.g. suspension concentrate to emulsiﬁable concentrate).
• In analogy to OECD Guidance Notes on dermal absorption (2011), a multi-to-one approach
might be acceptable in exceptional cases. It has to be demonstrated that dermal absorption of
a variety of products is always in the same range and that the formulation of the product
under evaluation is covered by the tested formulations in order to accept an overall value
based on a multi-to-one approach.
6.3. Data on the active substance
Flow chart 6.
Data generated with the unformulated active substance should only be used when the formulation
under evaluation is very closely related to the vehicle used in the study with the active substance, in
terms of solvent, surfactant content, skin irritancy and active substance content.
6.4. Microencapsulated formulations
See EFSA PPR Panel (2011), section 5.6.
The dermal absorption values used in exposure assessments should, by default, be based on the
product within the capsules. If acceptable exposure assessments cannot be achieved with this
approach, a case-by-case evaluation based on the properties of the encapsulated product relevant to
speciﬁc exposure scenarios can be performed:
• If the capsule is shown to remain intact within the formulation over 2 years (standard storage
stability test), then any exposure to the concentrate during mixing and loading can be
assumed to be to the encapsulated product and the dermal absorption value for the
encapsulated concentrate can be used, if available.
• If the capsule is seen to remain intact on dilution and throughout the application process (e.g.
through pressurised spray nozzles), then exposures relating to the time of application can be
based on the dermal absorption value for the diluted encapsulated product, if available.
• Dermal absorption values of the product within the capsule should be used if the integrity of
the capsule has not been demonstrated and in all cases for re-entry workers and residents
(see Section 5.10) since they are likely to be exposed to the material within the capsules that
Table 4: Permitted variation for active substance in similar formulations (from ‘Manual on
development and use of FAO and WHO speciﬁcations for pesticides’, 2016)
Initial concentration range of the
constituent (% w/w)
Permitted (relative) variation (%)
≤ 2.5 15 for homogeneous formulations (EC, SC, SL),
or 25 for heterogeneous formulations (GR, WG)
2.5 < c ≤ 10 10
10 < c ≤ 25 6
25 < c ≤ 50 5
≥ 50 2.5
c: concentration; EC: emulsiﬁable concentrate; SC: suspension concentrate; SL: soluble concentrate; GR: granules; WG: water-
dispersible granules.
14 http://www.fao.org/fileadmin/templates/agphome/documents/Pests_Pesticides/Specs/JMPS_Manual_2016/3rd_Amendment_
JMPS_Manual.pdf
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needs to be released in order to be effective. Should dermal absorption studies be available for
the active substance both in a concentrated solution and in a dilution, the higher of the two
ﬁgures should be used for assessment of dermal exposure for workers and residents.
6.5. Use of other information
6.5.1. QSARs and other mathematical models
See Appendix D.
The use of existing QSAR approaches for prediction of dermal absorption of active substances from
pesticide products should be evaluated using a homogeneous data set of PPPs (e.g. according to
OECD criteria). Until after such an evaluation a good predictive model has been identiﬁed, the use of
QSARs or other mathematical models for the prediction of dermal absorption is not recommended.
6.5.2. Information on related active substances (read across)
See EFSA PPR Panel (2011), section 5.5.
The use of data on related active substances needs to be considered on a case-by-case basis,
taking account of the properties of the active substances and formulations and the uncertainties in the
data sets. If such an approach is applied, sufﬁcient reasoning must be provided.
Molecules of very similar structure (e.g. ethyl substituent replacing methyl) and physicochemical
properties would be expected to have similar dermal absorption characteristics in the same
co-formulants.
Similarly, it might be possible to interpolate data from a number of similar active substances for
drawing conclusions on a new active substance that is within the series. For instance, if the dermal
absorption of a group of ﬁve closely related active substances in similarly formulated products is
between 15% and 20%, it is reasonable to conclude that a sixth compound in the series would have a
dermal absorption of around 15–20% if it has a similar formulation. However, it would not be
appropriate to extrapolate data from a series of three closely related compounds with dermal
absorption values of 2–12% based on signiﬁcantly different formulations.
6.5.3. Comparison of oral and dermal toxicity data
It is not recommended to derive the dermal absorption of a compound by comparing the toxicity
produced at different dose levels via the oral and dermal routes.
For the limitations, conditions and circumstances when this approach might be applied see the
EFSA PPR Panel (2011), section 5.2.
7. Data presentation in assessment reports
In order to aid the independent evaluation of dermal absorption data, without needing to go back
to the full study report, it is recommended that, as a minimum, the information given in Table 5 is
presented.
Table 5: Template with minimum information on dermal absorption studies to be presented in
assessment reports
In vitro and in vivo studies
Material/product tested (name/code number)
Type of formulation
Concentration of active substance in the formulation
Vehicle used (if any)
Dilution rates
Surface area dose in micrograms of active substance per cm2
Exposure time
Sampling duration (time of last sample)
Animal species/strain and skin sample source/application site
Group size/number of replicates/donor’s ID for replicate
Total recovery (individual values for replicates, mean values  SD)
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Modiﬁcations to this template will be required to match study designs, e.g. if tape stripping is not
performed or if all the strips are pooled.
A template (Excel ﬁle) to support calculations for dermal absorption from in vitro studies has been
provided by BfR and published as supporting information. The WG conﬁrms the template is in line with
the requirements in the EFSA guidance and recommends using the template as part of the dossier.
8. Flow charts
Flow chart 1a: Procedure to select default absorption values.
Flow chart 1b: Procedures to follow when there are no dermal absorption data on the actual
formulation under evaluation.
Flow chart 2: General procedure for decision of dermal absorption value of plant protection
products.
Flow chart 3: Procedures to follow when using dermal absorption data generated at dilutions
different to those representing ‘in use’ conditions.
Flow chart 4a: Consideration of stratum corneum and application site residues in vitro.
Flow chart 4b: Consideration of stratum corneum and application site residues in vivo.
Flow chart 5: Procedures to follow when reading across dermal absorption data between
formulation types.
Flow chart 6: Procedures to follow when extrapolating dermal absorption data on an active
substance to a formulated product.
In vitro and in vivo studies
Amount absorbed (individual values for replicates, mean values  SD)
Samples contributing to the amount absorbed and samples removed as outliers (with justiﬁcation)
Type of tape strip used
In vivo studies
Amount in excreta (individual values, mean values  SD)
Amount in carcass (individual values, mean values  SD)
Amount in exhaled volatiles/CO2 (individual values, mean values  SD)
75% excreted in ﬁrst half of study?
Amount in stripped application site (individual values, mean values  SD)
Amount in tape strips 3 to ∞ (individual values, mean values  SD)
Amount in tape strips 1 + 2 (individual values, mean values  SD)
Amount in application site washes (individual values, mean values  SD)
Swabbing
In vitro studies
Type of diffusion cell
Receptor ﬂuid composition
Speciﬁcation of solubility in receptor ﬂuid as recommended
t0.5 value
Amount in receptor ﬂuid and chamber wash (individual values for replicates, mean values  SD)
Amount in stripped skin sample (individual values for replicates, mean values  SD)
Amount in tape strips 3 to ∞ (individual values for replicates, mean values  SD)
Amount in tape strips 1 + 2 (individual values for replicates, mean values  SD)
Amount in skin sample washes (individual values for replicates, mean values  SD)
Swabbing
SD: standard deviation.
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Is the formulation one of the 
following types: EC, EW, SE, DC, 
OL / OF, OD, ES, ME (organic 
solvent-based)  
Or 
 CB, CS, GEL / GD, RB, ZC, PS, AI 
(“other”)? 
Default = 25% 
Is the formulation one of the 
following types: SL, SC, FS, FL 
(=SC) (water-
based/dispersed)  
Or 
 WP, WG / WDG, SG, SP, DS 
(solid)? 
Default = 10% Default = 70% Default = 50%
Are you 
evaluating an 
undiluted 
formulation? 
Are you 
evaluating an 
undiluted 
formulation? 
Flow chart 1a: Procedure to select default absorption values
Guidance on dermal absorption
www.efsa.europa.eu/efsajournal 24 EFSA Journal 2017;15(6):4873
needs to be generated
START
No further data
generation or
evaluation
requiredUse oral absorption value
chosen to set AOEL**
Is information available on
related formulations or the
active substance?
Data or a specific caseSee charts 3, 5 and 6
Are all
exposure
assessments
below the
AOEL?
Are all
exposure
assessments
below the
AOEL?
* a.s.: active substance
** Approach acceptable only in limited range of circumstances (see Section 6.1.1).
Derive default values
using flow chart 1a
Flow chart 1b: Procedures to follow when there are no dermal absorption data on the actual
formulation under evaluation
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Flow chart 2: General procedure for decision of dermal absorption value of plant protection products
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Flow chart 3: Procedures to follow when using dermal absorption data generated at dilutions
different to those representing ‘in use’ conditions
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Flow chart 4a: Consideration of stratum corneum and application site residues in vitro
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Flow chart 4b: Consideration of stratum corneum and application site residues in vivo
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Flow chart 5: Procedures to follow when reading across dermal absorption data between formulation
types
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Flow chart 6: Procedures to follow when extrapolating dermal absorption data on an active
substance to a formulated product
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Glossary and Abbreviations
ADME study Absorption, distribution, metabolism, excretion study.
Area under the curve (AUC) Area under the plasma drug/chemical concentration versus time curve; a
measure of drug/chemical exposure.
Dermal absorption The movement of a chemical from the outer surface of the skin into the
circulatory system, eventually leading to systemic exposure towards the
chemical (dermal bioavailability) and its metabolites. Also called as
percutaneous absorption.
Dermal penetration The movement of a chemical from the outer surface of the skin into the
epidermis, but not necessarily into the circulatory system.
Dermal permeation The penetration through one layer into another, which is both
functionally and structurally different from the ﬁrst layer.
Flux The amount of material crossing a deﬁned area in a set time. A chemical
with a high dermal ﬂux will be absorbed more readily than a chemical
with a lower ﬂux.
Full-thickness skin Full-thickness skin preparations consist of a 500–1000 lm thick skin
sample, incorporating the stratum corneum, viable epidermis, and
dermis.
Lag-phase The time taken for the absorption of a chemical across the skin to reach
a linear ﬂux. Can be determined by extrapolating the line of linear ﬂux
back to the intercept at the X-axis of an absorption: time plot.
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Log Pow The logarithm of the partition coefﬁcient of a substance between octanol
and water (i.e. the relative maximum amount of a chemical that will
dissolve in octanol and in water). A compound with a solubility of 100 g/L
in octanol and 1 g/L in water would have a log Pow of 2.0.
Split-thickness skin Split-thickness (dermatomed) skin consists of 200–400 lm thick sample,
in which the lower dermis has been removed. A surgical instrument for
cutting skin grafts, called dermatome, is used to obtain samples of
uniform shape and thickness.
Stratum corneum The outermost layer of the epidermis. Consists of several layers of non-
viable cells (typically 15–20), the outermost cells are lost by sloughing
off. Varies in thickness with anatomical site. It presents the major barrier
to dermal absorption.
Tape stripping A procedure performed at the end of a dermal absorption study that
involves the application of adhesive tape to the area of skin that was
exposed to a chemical. An even (often predetermined) pressure is
applied to the tape before it is removed, taking a layer of stratum
corneum cells with it. The tape strip is then analysed to determine the
amount of chemical that was present in the removed stratum corneum.
The procedure is repeated to remove sequentially lower layers of the
stratum corneum.
Transfer coefﬁcient The rate at which dislodgeable foliar residues can be transferred to a
worker during a speciﬁed activity (expressed in terms of the area of
contaminated foliage or fruit from which residues are transferred per
hour).
t0.5 mean relative permeation into the receptor ﬂuid occurring within half of
the sampling period.
AOEL acceptable operator exposure level
a.s. active substances
BfR Bundesinstitut f€ur Risikobewertung
CPO conditional predictive ordinate
DIC deviance information criterion
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals
ECPA European Crop Protection Association
FDSP ﬁnite dose skin permeation
GLP Good Laboratory Practice
ML marginal likelihood
MW molecular weight
OECD Organisation for Economic Co-operation and Development
PPP plant protection product
PPR EFSA Panel on Plant Protection Products and their Residues
QSAR quantitative structure–activity relationship
RF receptor ﬂuid
SCCS Scientiﬁc Committee on Consumer Safety
SCoFCAH Standing Committee on the Food Chain and Animal Health
WAIC Watanabe-Akaike information criterion
WG Working Group
WHO World Health Organization
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Appendix A – Human in vitro dermal absorption data sets: new versions15
1. New ECPA data set
1.1. Data and methodology
European Crop Protection Association (ECPA) data pooled from 295 Good Laboratory Practice (GLP)
and OECD 428-compliant in vitro human dermal absorption studies and collected into a data set
(Aggarwal et al., 2014, 2015) were assessed by EFSA as described in the EFSA Scientiﬁc Report
‘Assessment of new scientiﬁc studies on human in vitro dermal absorption’ (EFSA, 2015). Individual
values were not provided in the data set, in which mean values and standard deviations of dermal
absorption parameters were reported at different levels of completeness. A new version of the ECPA
data set was then created and submitted by ECPA, including individual replicate values from the
human in vitro dermal absorption experiments. Moreover, additional and updated information was
included in the new ECPA data set, such as: (i) added information: donor id, donor sex, donor age,
number of replicates for each donor, replicate id; and (ii) updated information: skin region, %
absorption at t0.5.16
The new data set, covering physicochemical properties for 152 agrochemical active substances
(a.s.), 19 formulation types, tested at different concentrations, provided 5,180 records in total.
Exposure and sampling time were 6–10 h and 24 h, respectively.
A plausibility check to verify the correctness of the data set from sources (study reports) was
undertaken applying a protocol that, as a ﬁrst step, aimed to identify relevant ﬁndings to be
subsequently checked. Comparison was performed among data in the new ECPA data set (including
individual replicates data) vs data in the ﬁrst version of the ECPA data set (including mean values
only). The relative deviation was calculated as the percentage ratio between mean value in the new
data set and mean value in the ﬁrst version of the data set. For acceptability purposes, a threshold for
the relative variation was established (15%) so that only deviations above the threshold were
considered initial ﬁndings and further evaluated in the plausibility check.
Both the parameters quantiﬁed in the dermal absorption experiment (non-absorbed dose, directly
absorbed dose, whole skin dose, stratum corneum dose, tape strip 1 and 2 dose, overall recovery) and
the calculated parameters (t0.517 and absorbed dose) were evaluated. Thus, 6,080 pairs of means
were compared (760 records checked for eight parameters).
1.2. Results
Application of the plausibility protocol identiﬁed 270 initial ﬁndings (relative variation between two
mean values above 15%) out of 6,080 pair of mean values (4.4%).
For these ﬁndings, the plausibility check of data in the data set vs study reports allowed correction
of the new ECPA data set for 56 ﬁndings,18 reducing the number of ﬁndings to 214 (3.5%).
Out of these 214 ﬁndings, 14019 were found to be accurate in the new ECPA data set. The
remaining 74 relevant ﬁndings (1.2%) were due to missing data20 and the t0.5 calculation.21
Individual values for tape strips 1 and 2 not found in the study reports but calculated from the
relative amount in tape strip 1 and 2 were retrieved in the new data set.
In the end, from the analysis of normalised data found from the plausibility check, and considering
the relevant number22 of recovery mean values outside EFSA acceptability (< 95%), it was decided to
15 The combined ECPA and BfR data sets used for the statistical analysis are provided as supporting information (XLS ﬁle).
16 t0.5: The mean relative permeation into the receptor ﬂuid occurring within half of the sampling period.
17 t0.5 data were only partially reported in the ﬁrst version of the ECPA data set and the plausibility check for this parameter was
performed accordingly.
18 34 mistakes in individual replicates data and/or mean values; 18 normalised data (low recovery) without justiﬁcation; 3 not
clear in the study reports (receptor ﬂuid and ‘swabbing’ values, causing discrepancies for the calculation of directly absorbed
dose; receptor ﬂuid value was used); 1 mistake in the study reports.
19 40 mistakes in the ﬁrst version of the data set; 100 deviations due to whole skin dose calculation, accurate in the new data
set.
20 Reports for six studies in the ECPA data set were missing (not submitted to EFSA); 43 deviations were due to not reported
tape strips 1 and 2 individual values in the study reports.
21 t0.5 calculation for different approaches (mean of % absorbed at 12 h relative to 24 h or as % of the mean absorbed at 12 h
relative to 24 h).
22 856 records out of 5,180.
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apply the less stringent OECD (2011) requirement for the mean mass balance recovery, excluding
low23 (< 90%) and high24 (> 110%) recovery mean values from the new data set and not normalise/
use some data (as the justiﬁcation was not provided). On the basis of this, ﬁnal records in the new
ECPA data set are 4972.
1.3. Conclusions
The plausibility check of the data in new ECPA data set (including individual replicate values)
highlighted the high quality in data entry from the source (study report), discrepancies being found for
only 1.2% of checked data. In particular, it was shown that the different approaches used to calculate
t0.5 were leading to different outcomes and the need for clariﬁcation in the guidance was identiﬁed. In
addition, it was noted that for a relevant number of records low and high mean mass balance
recoveries were reported and it was decided to exclude from the statistical analysis records showing
recovery mean values outside the OECD acceptability criteria.
2. New BfR data set
2.1. Data and methodology
The German Federal Institute for Risk Assessment (BfR) data set containing 480 records GLP and
OECD 428-compliant in vitro human dermal absorption studies was assessed by EFSA, as described in
the EFSA Scientiﬁc Report Assessment of new scientiﬁc studies on human in vitro dermal absorption
(EFSA, 2015). Although mean values and standard deviations of dermal absorption parameters were
reported, individual values were not provided in this data set. Also, t0.5 values were not included.
A new version of the data set was then created and submitted by BfR, including individual replicate
values from human in vitro dermal absorption experiments. When available from the original reports,
additional and updated information were included in the new data set, such as: (i) added information:
donor id, donor sex, donor age, number of replicates for each donor, replicate id; and (ii) updated
information: skin region, % absorption at t0.5.
As some overlap was noted between the original ECPA and BfR data sets, the updated BfR data set
did not include those duplicates. Accordingly, the new data set, covering physicochemical properties
for 94 agrochemical active substances, 23 formulation types and subtypes, tested in different
formulations and at different concentrations, provided 2,273 individual records from 377 experiments
in total. Exposure and sampling time were 6–24 h and 24 h, respectively. The structure of the new
database was aligned by BfR with the EFSA requirements and reported, for example, separate values
for total stratum corneum (all tape strips) and tapes strips 1 and 2, rather than only the stratum
corneum excluding tape strips 1 and 2.
A quality control check was applied to the data set to verify the correctness of the data set from
sources (study reports). This was undertaken applying a protocol that, as ﬁrst step, aimed to identify
relevant ﬁndings to be subsequently checked. A comparison was performed among data in the new
BfR data set (including individual replicates data) vs data in the ﬁrst version of the BfR data set
(including mean and standard deviation values). The relative deviation was calculated as the
percentage ratio between mean value in the new data set and mean value ﬁrst version of the data
set). For acceptability purposes, a threshold for the relative variation was established (15%) so that
only deviations above the threshold were considered to be initial ﬁndings and further evaluated in the
plausibility check. Both the parameters quantiﬁed in the dermal absorption experiment (directly
absorbed dose; overall recovery) and the calculated parameters [absorbed dose (i.e. directly
absorbed + whole skin  tape strips 1 and 2); t0.5] were evaluated. A total of 1,377 pairs of means
were compared (377 experiments records checked for three or four parameters, as available in the
ﬁrst version).
A second step in the plausibility check of the individual record data was performed to address
endpoints for which a direct comparison of means across replicates with the ﬁrst version of the data
set, as described in the EFSA Scientiﬁc Report issued in 2015, was not possible due to differences in
the database structure, as described above. A set of 754 means was compared in this second step
(377 experiments 9 2 additional parameters). Thus, in total, 2,131 (1,377 + 754) pairs of means were
checked.
23 141 out of 5,180 records were found < 90 and were removed from the new data set.
24 67 records out of 5,180 were found > 110 and were removed from the new data set.
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2.2. Results
Application of the plausibility protocol identiﬁed 23925 initial ﬁndings (relative variation between 2
mean values above 15%) out of 1,377 + 754 = 2,131 pair of mean values (11%).
Out of these, 5526 were traced to errors in the new data set. Correction of the new data set was
performed using the original source data. This reduced the number of remaining ﬁndings to 184
(8.6%).
Another 2627 ﬁndings were due to inappropriate rounding or erroneous pairing of means. These
deviations were not considered relevant and no correction was triggered. Accordingly, the number of
relevant ﬁnding was 158 (7.4%).
Out of these 158 ﬁndings, 13028 were found to be accurate in the new BfR data set. The remaining
28 relevant ﬁndings (1.3%) were due to t0.5 calculation,29 normalised data without justiﬁcation,30 and
reporting of non-detects.31
As for the ECPA data set, it was decided to apply the less stringent OECD (2011) requirement for
the mean mass balance recovery, excluding low32 (< 90%) and high33 (> 110%) recovery mean values
from the new data set. In addition, it was decided not to accept normalisation of the data for the
purpose of this analysis, reducing the ﬁnal number of records for individual values to 2,258.
2.3. Conclusions
The plausibility check of the data in new BfR data set (including individual replicate values)
highlighted the high quality of data entry from the source (study report), discrepancies being found for
only 1.3% of the checked data. In particular, different mathematical approaches used to calculate t0.5
leading to different outcomes were found, conﬁrming the need for clariﬁcation in the guidance. Also,
different approaches to the handling outliers (i.e. identiﬁcation and potential exclusion) were noted
when calculating mean values for experimental groups. More detailed guidance is provided on these
issues to achieve better harmonisation in study evaluation.
25 156 from step 1 and 83 from step 2.
26 47 from step 1 and 8 from step 2.
27 11 from step 1 and 15 from step 2.
28 68 from step 1 and 62 from step 2.
29 16 ﬁndings.
30 8 ﬁndings were due to normalisation of mean data to overall recovery by the authors for two dose groups of one study.
31 4 ﬁndings resulted from differences in reporting of non-detects (values below limit of quantiﬁcation (LOQ)) between the data
sets.
32 260 records.
33 128 records.
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Appendix B – Statistical analysis
1. Basis for the treatment of variability within the results
The values shown for the multiplication factor (k) in Table 1 (Section 5.3) are based on a
mathematical model. Here, the model is described and its applicability evaluated; in particular, how it
compares with the OECD approach which suggests using the highest replicate in risk assessment when
the variability is high (OECD, 2011).
Suppose that a sample of n values x1,. . ., xn is drawn from a normally distributed population. Then,
the standard 95% conﬁdence interval for the population mean is well known:
x  t sﬃﬃﬃ
n
p (B1)
where x is the sample mean, s is the sample standard deviation and t* is the value which is exceeded
with probability of 2.5% by the Student’s t distribution having n  1 degrees of freedom. In Table 1,
k ¼ t= ﬃﬃﬃnp .
The upper 97.5% conﬁdence limit is the upper end of the 95% conﬁdence interval and
underestimates the population mean for 2.5% of samples. This holds true for any n. By contrast, when
n = 4, the sample maximum underestimates the population mean for 6.3% of samples from a normal
distribution and this percentage decreases as n increases. When n = 8, it becomes 0.4%. So, the
degree of conservatism obtained by using the maximum changes greatly with the sample size.
Moreover, it is known mathematically that the most statistically efﬁcient way to estimate an upper limit
for the population mean is to take the upper limit conﬁdence limit. Thus, not only does the overall
level of conservatism change with n if the sample maximum is used, but also the amount of
conservatism varies more between samples if the maximum is used.
Therefore, it is sensible to seek an alternative to using the sample maximum. However, absorption
replicates are not normally distributed, even within a single study. They tend to be skewed quite
substantially: for the data set (ECPA + BfR) described in Appendix A, 77% of samples have positive
skew, the mean skewness is 0.5 and the standard deviation of skewness is 0.7. One solution to this
problem is to transform data before making statistical calculations. In this case, the logit
transformation:
lnðx=ð1 xÞÞ
has several beneﬁts: the average skewness is close to 0 for the transformed data; there is little
evidence that skewness depends on the amount of absorption; and the variability of the transformed
data is stabilised so that it no longer depends strongly on the level of absorption (homogeneity). With
respect to these criteria, the logit transformation was found to be superior to either the probit or
arcsine transformations which are common alternatives. The logit transformation is essentially
indistinguishable from log transformation when the fraction absorbed is small, but stretches the scale
out better for higher levels of absorption.
The above argument that the upper conﬁdence limit is preferable to the sample maximum for
normally distributed data is much more directly applicable to logit-transformed absorption data than to
raw (untransformed) absorption data since normal distributions are symmetric. Note that, due to low
power, there is little point in testing for normality for the small samples sizes that are usual in
absorption studies. To apply the upper conﬁdence limit to transformed data, one would ﬁrst calculate
the logit of each replicate, then calculate the upper conﬁdence limit (UCL) from the transformed data
and ﬁnally undo the logit transformation by calculating:
expðUCLÞ=ð1 þ expðUCLÞÞ:
The resulting value would be a 97.5% upper conﬁdence limit for the population median fraction
absorbed. This is because the mean and median are the same for symmetric distributions and the
median of logit transformed values is the same as the logit of the median of untransformed values.
However, logit transformation requires more effort to apply than simply calculating the upper
conﬁdence limit directly using the raw data. As a practical compromise, it is suggested to apply the
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upper conﬁdence limit calculation to the untransformed absorption values without using any
transformations. An empirical investigation follows of the performance of the method when applied to
the data set (ECPA + BfR) described in Appendix A.
Figure B.1 shows box plots, by sample size n, of the ratio of the upper conﬁdence limit obtained using
the logit approach to the upper conﬁdence limit obtained by applying equation 1 to the raw data. It
shows that the logit approach is typically more conservative for n = 4, slightly more conservative for
n = 5, about the same for n = 6 and slightly less conservative for n = 7 and n = 8. There is not much
difference overall for n ≥ 5. There are quite large differences in outcome for some samples but this
reﬂects the fact that small sample sizes generally lead to variable outcomes for any statistic.
Figure B.2 shows box plots, by sample size n, of the ratio of the upper conﬁdence limit obtained
using the raw data to the maximum of the sample. For n = 4, it shows that the upper conﬁdence limit
is more conservative than the maximum even though it is less conservative than when the logit
transformation is used. So, for n = 4, the upper conﬁdence limit is a step in the right direction. For
n ≥ 5, the upper conﬁdence limit is, as desired, less conservative than the maximum and is not very
much less conservative than when the logit transformation is used.
Figure B.1: Box plots, by sample size n, of the ratio of logit-transform based upper conﬁdence limit
to raw data upper conﬁdence limit. Red line highlights where the limits are equal and
blue lines where the ratio is between 0.9 and 1.1
Guidance on dermal absorption
www.efsa.europa.eu/efsajournal 39 EFSA Journal 2017;15(6):4873
Finally, the upper conﬁdence limit calculation assumes that the sampled values are independent.
When the number of donors is less than the number of samples, there is some correlation between
samples from the same donor. In principle, the values for k in the Table 1 in Section 5.3 should be
increased to allow for this correlation. The typically small sample size means that the estimate of this
correlation is extremely variable between samples; on average, it was found to be 0.3 and this could
be considered a sensible value to use. On that basis, Monte Carlo simulation was used to calculate the
value of k for each value of n in the Table 1 in section 5.3, making the assumption that there were two
donors for n < 5, three donors for n = 5 and four donors for n > 5, and that replicates were as evenly
balanced across donors as possible. In each case, the increase in k compared to the value in the
Table 1 (Section 5.3) was less than 20%. Empirically, using untransformed data, the upper conﬁdence
limit would increase by less than 10% (e.g. from 1% absorption to 1.1% absorption) for 90% of
samples and never by more than 15%. Since the use of the maximum in any case makes no allowance
for correlations, the values of k in the table were left unchanged.
2. Pro-rata extrapolation for untested dilutions
Figure B.3 shows data from studies in the data set (ECPA + BfR) described in Appendix A, where
the same active substance was tested at more than one dilution. Replicates were averaged on a logit
scale and back-transformed to the original scale as described in Section 1 of Appendix B. It also shows
lines highlighting pro-rata extrapolation and the proposal of Aggarwal et al. (2014, 2015) to make no
extrapolation for less than twofold dilution and to cap pro-rata extrapolation at a maximum of ﬁvefold
increase in absorption. Points are coloured light blue when pro-rata extrapolation would predict
absorption in excess of 30%, the situation for which Aggarwal et al. (2014, 2015) further propose
capping absorption at 30%.
There were, in total, 8 data points above the red line highlighting the EFSA pro rata approach for
extrapolation (partially not resolved in Figure B.3). For these data points, mean dermal absorption
percentages increased by a factor that was higher than the quotient of the concentrations tested. For
seven of these eight cases, the ratio between increase in mean dermal absorption and decrease in
concentration tested was between 1.02 and 1.26, rather than the worst-case of 1.00 assumed in the
EFSA pro-rata approach. However, this level of deviation is within the limits of variability observed for the
test method and would not invalidate the approach. For the remaining case, the mean dermal absorption
increase 2.53-fold as strong as greater than would be expected when applying the EFSA pro-rata
approach. However, re-inspection of the data showed that automated data analysis lead to inappropriate
comparison of a dilution of a product with another dilution of the same product to which additional
surfactant was added while the difference in active substance concentration was minimal. Accordingly,
the larger than expected increase in dermal absorption could be attributed to the added co-formulant.
Figure B.2: Box plots, by sample size n, of the ratio of raw data upper conﬁdence limit to the sample
maximum. Red line highlights where the limits are equal
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As depicted in Figure B.3, several data points would be underpredicted by the extrapolation
approach proposed by Aggarwal et al. (2014, 2015) and the magnitude of underprediction can be
signiﬁcant (note logarithmic scale in Figure B.3).
3. Statistical modelling to support the setting of default values
For the purpose of calculations to support the setting of default values, two different statistical
modelling approaches were tried.34 Both were based on the data set (ECPA + BfR) described in
Appendix A and explored how variation in dermal absorption could be explained by physicochemical
properties of the active substance, by the type of formulation used, by properties of the skin sample
exposed and by experimental conditions (see Table B.1).
The physicochemical variables included log-partition coefﬁcient (log Pow), molecular weight (MW)
and water solubility. The active substance name was also included as a categorical variable in some
models to act as a proxy for differences between substances other than the provided physicochemical
variables. Because the data set (ECPA + BfR) included many different formulation types, they were
merged into four categories: organic solvent, water-based, solid and ‘other’. Grouping of formulations
types is based on information about the chemical composition of the tested product, the information
on the phase in which the active substance is dissolved or emulsiﬁed/suspended and the expectable
impact on dermal absorption (see Table B.2). Skin sample variables included skin type, sex and age.
The data set (ECPA + BfR) also includes skin source, skin region and donor id, which were disregarded
Figure B.3: Exploration of pro-rata extrapolation for dilutions. Each point corresponds to a study with
more than one dilution of the same active substance. The horizontal axis shows the ratio
of the concentrations for the two dilutions. The vertical axis shows the ratio of the
fraction absorbed (average of replicates) for the lower concentration to the fraction
absorbed at the higher concentration (average of replicates). Both axes are logarithmic.
The thick red line corresponds to pro-rata extrapolation and the thick blue line
corresponds to Aggarwal et al. (2014, 2015); points coloured light blue are cases where
pro-rata extrapolation would predict absorption in excess of 30%, i.e. where step 3 in
the extrapolation scheme proposed in section 4.7 of Aggarwal et al. (2014) would apply
Table B.1: Evaluated variables and corresponding parameters in the data set (ECPA + BfR)
Physicochemical properties (active
substances) and formulation (product)
Active substance code, MW, log Pow, water solubility, formulation
type, concentration tested, concentration status (concentrate/
dilution)
Skin sample Skin type, sex, age, donor, skin source, skin region
Experimental conditions Exposure duration, chamber type, mass balance recovery, receptor
medium
MW: molecular weight.
34 All R codes used for the analysis are provided as supporting information (HTML ﬁle).
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in most analyses since they were missing from many data records. The experimental condition
variables included log-concentration (mass and molar) of the active substance, duration of exposure,
chamber type, recovery and receptor medium.
Because the fraction of chemical absorbed must lie between 0 and 1, a standard regression is not
appropriate as it assumes that random variations are normally distributed. One statistical modelling
approach addressed this by using beta regression and the other by applying standard and mixed model
(also known as random-effects or multilevel) regression methods to the logit of the fraction absorbed.
Table B.2: Formulations categories. Grouping of formulation types in four categories based on the
tested product types in the data set (ECPA + BfR): (1) Primarily organic solvent-based,
(2) Primarily water-based/dispersed, (3) Solid, (4) Other
Code Description
Number
of studies
Details and justiﬁcation for grouping(a)
1 EC Emulsiﬁable
concentrate
90 The active substance is dissolved in suitable organic solvents,
together with any other necessary formulants. It should be in
the form of a stable homogeneous liquid, free from visible
suspended matter and sediment, to be applied as an emulsion
after dilution in water
DC Dispersible
concentrate
1 The active substance is dissolved in suitable organic solvents,
together with any other necessary formulants. It should be in
the form of a stable homogeneous liquid, free from visible
suspended matter and sediment, to be applied as a dispersion
after dilution in water
EW Emulsion, oil in
water
15 A stable emulsion of active substance(s) in an aqueous phase,
intended for dilution with water before use. The active
substance is normally a liquid and forms the dispersed oil
phase, but it is also possible to emulsify a solid or liquid active
ingredient dissolved in a water-immiscible solvent. EW are
emulsions with organic solvents as the inner phase in which
the active substance is dissolved
SE Suspo-emulsion 29 Multiphase formulation whereby an emulsiﬁed active
substance is combined with active suspended in water. SEs
are emulsions/suspensions with an organic solvents(s) as a
phase in which the active substance is dissolved
OL/OF Oil-miscible liquids 1 A solution of the active substance, together with any other
necessary formulants, in an organic solvent; no water is
contained. It should be free of visible suspended matter and
sediment, intended for dilution with organic liquid before use
OD Oil-based
suspension
concentrate
18 An oil dispersion is a stable suspension of active substance(s)
in an organic ﬂuid, which may contain other dissolved active
substance(s); no water is contained. It is intended for dilution
with water before use
ES Emulsion for seed
treatment
1 A water-based emulsion containing the active substance,
together with large amounts of organic solvents and any
necessary formulants including colouring matter. It should be
easy to homogenise, and suitable for dilution with water if
necessary, application to the seed either directly or after
dilution. ES are emulsions with organic solvents as inner
phase in which the active substance is dissolved
ME Microemulsion 3 A mixture of water, water-insoluble and water-soluble
components forming a visually homogeneous, transparent
liquid. One or more active substances may be present in
either the aqueous phase, the non-aqueous phase, or in both
phases. A variety of microemulsion formulations may be
prepared in which the aqueous phase can be considered the
dispersed phase, the continuous phase or, alternatively, where
the two phases are considered bicontinuous. In all cases,
microemulsions will disperse into water to form either
conventional emulsions or dilute microemulsions
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Code Description
Number
of studies
Details and justiﬁcation for grouping(a)
2 SL Soluble
concentrate
21 Water-based formulation in which a salt of pesticide acid is
dissolved in water, together with any other necessary
formulants. It should be in the form of a clear or opalescent
liquid, free from visible suspended matter and sediment, to
be applied as a true solution of the active substance in
water
SC Suspension
concentrate
121 A stable suspension of active substance(s) in an aqueous
continuous phase, intended for dilution with water before
use
FS Flowable
concentrate for
seed treatment
18 A suspension of ﬁne particles of the active substance in an
aqueous phase together with suitable formulants, including
colouring matter. After gentle stirring or shaking, the material
shall be homogeneous and suitable for further dilution with
water if necessary
FL Flowable 1 As described for the product, it is a SC formulation
3 WP Wettable powder 12 A homogeneous mixture of the active substance(s) together
with ﬁller(s) and any other necessary formulants. It should be
in the form of a ﬁne powder free from visible extraneous
matter and hard lumps
WG/WDG Water-dispersible
granules
57 Intended for application after disintegration and dispersion in
water by conventional spraying equipment
SG Water-soluble
granules
5 Granules containing the active substance, and, if required,
suitable carriers and/or necessary formulants. It shall
be homogeneous, free from visible extraneous matter and/
or hard lumps, free ﬂowing, and nearly dust-free or
essentially non-dusty. The active substance should be
soluble in water
SP Water-soluble
powder
2 A homogeneous mixture of the active substance, together
with any necessary formulants. It should be in the form of a
powder to be applied as a true solution of the active
substance after solution in water, but which may contain
insoluble inert ingredients
DS Powder for dry
seed treatment
1 A powder for application in the dry state directly to the seed;
a homogeneous mixture of the active substance together with
suitable ﬁllers and any other necessary formulants including
colouring matter. It should be in the form of a ﬁne free-
ﬂowing powder, free from visible extraneous matter and hard
lumps
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3.1. Beta regression modelling
In this part of the analysis, a family of Beta regression models was used, a type of regression
model tailored to analyse data with a continuous response variable lying in (0,1). The response
variable is assumed to be Beta distributed, which in the usual parameterisation has probability density
function
fðyÞ ¼ Cðaþ bÞ
CðaÞCðbÞ y
a1ð1 yÞb1
for y 2 (0, 1) with parameters a, b, > 0. Because the expectation l relates to parameters a and b
through the equation l = a/(a + b), this parameterisation is not the most convenient for regression
analysis and the alternative parameterisation below is used in the Beta regression framework:
fðyÞ ¼ Cð/Þ
Cðl/ÞCðð1 lÞ/Þ y
l/1ð1 yÞð1lÞ/1
with l 2 (0, 1) (mean) and / > 0 (precision parameter), which corresponds to the change of variable
l = a/(a + b) and / = a + b.
The Beta regression model considered in the present analysis assumes that the expectation l of
the response y relates to a vector of explanatory variables x = (x1, . . . , xp)
t through the logistic
Code Description
Number
of studies
Details and justiﬁcation for grouping(a)
4 CB Bait concentrate 1 A solid or liquid intended for dilution before use as a bait.
Sugar or other food ingredients or components like talcum are
often the main compounds
CS Capsule
suspension
6 A stable suspension of microencapsulated active substance in
an aqueous continuous phase, intended for dilution with water
before use
GEL/GD Gel for direct
application
1 A gel-like preparation, intended to be applied undiluted. A gel
for direct application consists of one or more active
substances, a structuring agent and other formulants if
appropriate. The active substance is homogenised in suitable
solvents, together with any other necessary formulants. It
should be in the form of a clear or opalescent gel, free from
visible suspended matter and sediment. These formulations
are different from organic or water-based formulations
RB/Pellets/
Wax block/
Pasta bait
Bait (ready for
use; paste, wax
bloc, pasta bait
included)
6 A formulation designated to attract and be eaten by the
target pests. Wax blocs or paste baits are included. For
example, in the case of a rodenticide, it is a solid bait and is
based on grains, cereals and/or large amounts of wax. RB
differs from other solid formulations
ZC CS and SC
mixture
3 A mixed formulation of CS and SC and is a stable suspension
of microcapsules and solid ﬁne particles, each of which
contains one or more active substances. The formulation is
intended for dilution into water prior to spray application
PS Seed coated with
a pesticide
1 Seed coated with a pesticide. PS formulations probably contain
only the active substance, colour and carrier formulants
AI Experimental
solution of active
substance in
solvent
4 The vehicle can be organic or water-based. Because of the
absence of other co-formulants, these solutions are not
comparable with organic- or water-based formulations
Excluded from statistical analysis:
XX/NA 6 No information on formulation type available
Numbers of studies are reported for each formulation type in the data set (ECPA + BfR).
(a): Based on the FAO/WHO, 2016.
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function, namely l ¼ 1=ð1þ expðxtbÞÞ where b is a vector of unknown regression parameters. This
means that xtb is the logit of l.
The explanatory variables considered were those listed in Table B.1 with the exception of skin
donor, source and region which are missing from many records. For the modelling for which results are
reported in detail in the rest of Section 3.1 of Appendix B, concentration tested was included using the
molar concentration. Moreover, formulation type and concentration status (concentrate/dilution) were
included via a single synthetic categorical variable (named FormTypeConcDil in Tables B.3 and B.4
below) combining the grouped formulation described earlier (organic solvent, water-based, solid and
‘other’) with the concentration status. The ﬁve levels of that categorical variable were: organic solvent
formulation tested as concentrate, water-based formulation tested as concentrate, solid formulation
tested as concentrate, other formulation tested as concentrate and any formulation tested as dilution.
Active substance is a factor (categorical variable) with 238 levels and stands as a surrogate for non-
observed structural information about the various active substances. It was treated as a random
effect, making the model a mixed model. Receptor medium is also a factor which after aggregation of
the initial 180 levels has 14 levels. It was also treated as a random effect. The analysis was performed
on those records in the data set for which the recorded absorption was greater than 0% and less than
100%.
Each variable being included or not in a submodel, the list of 13 explanatory variables gives raise to
213 = 8192 submodels. For each submodel, parameters were estimated and several model ﬁt criteria
were computed: the Deviance Information Criterion (DIC), the Marginal Likelihood (ML), the
Watanabe-Akaike information criterion (WAIC) and the Conditional Predictive Ordinate (CPO).
Computing model ﬁt criteria for those 8,192 submodels allows quantiﬁcation of how each explanatory
variable contributes to explaining variation in dermal absorption while accounting for potential
confounding effects. Computations were made using the R package INLA (Rue et al., 2009).
3.1.1. Results
A strong congruence in the way the various model ﬁt criteria ranked the 8192 submodels was
observed, in particular among DIC, WAIC and CPO. Therefore, it was decided to focus on DIC for
subsequent analyses. DIC was used to rank the various submodels and for each k from 1 to 13, the
best submodel containing exactly k variables was identiﬁed. The results are given in Table B.3.
Table B.3: List of best k-variable models in terms of Deviance Information Criterion.
k (number of
explanatory
variables)
Best submodel DIC
1 FormTypeConcDil 22,021.54
2 logMolConc + AScode 25,124.00
3 logMolConc + ReceptMedium + AScode 25,438.65
4 logMolConc + Duration + ReceptMedium + AScode 25,612.36
5 FormTypeConcDil + logMolConc + Duration + ReceptMedium + AScode 25,723.63
6 FormTypeConcDil + logMolConc + SkinType + Duration +
ReceptMedium + AScode
25,809.91
7 WaterSolub + FormTypeConcDil + logMolConc + SkinType + Duration +
ReceptMedium + AScode
25,844.12
8 WaterSolub + FormTypeConcDil + logMolConc + SkinType +
Duration + ChamberType + ReceptMedium + AScode
25,873.17
9 WaterSolub + FormTypeConcDil + logMolConc + SkinType + Age +
Duration + ChamberType + ReceptMedium + AScode
25,901.05
10 logMW + WaterSolub + FormTypeConcDil + logMolConc + SkinType + Age +
Duration + ChamberType + ReceptMedium + AScode
25,925.38
11 logMW + WaterSolub + FormTypeConcDil + logMolConc + SkinType + Age +
Sex + Duration + ChamberType + ReceptMedium + AScode
25,942.34
12 logMW + WaterSolub + FormTypeConcDil + logMolConc + SkinType + Age +
Sex + Duration + ChamberType + ReceptMedium + AScode + Recovery
25,950.67
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This ranking is helpful to understand which variables explain best variation in dermal absorption.
The most striking change in DIC is from k = 1 to k = 2 when the active substance code appears for
the ﬁrst time and it should be noted that it appears in all subsequent models. The models in Table B.3
are only a small subset of all models ﬁtted and there are often other models with the same number of
explanatory variables which exhibit nearly as good performance.
All models from k = 2 onwards include active substance code as an explanatory variable and all
from k = 3 onwards include receptor medium. For the active substance random effect term, the model
coefﬁcients are substance-speciﬁc and can be estimated only for substances present in the data set
(ECPA + BfR). A model based on the active substance random effect term is, therefore, unable to
provide a substance-speciﬁc prediction of dermal absorption for a substance not in the data set
(ECPA + BfR) although it is possible to make a generic prediction that should cover a speciﬁed
percentage of substances. Consequently, a model which includes the active substance code or the
receptor medium poses some challenges for designing default values since the random effects aspect
of either variable must be addressed. This is technically difﬁcult to do for the Beta regression model
ﬁtted using INLA and this aspect is therefore addressed later in Section 3.2 of Appendix B using
random effects logit regression models.
In a second step, for each k from 1 to 11, the best submodel containing exactly k variables,
excluding active substance code and receptor medium, was identiﬁed. These submodels are given in
Table B.4. The synthetic variable FormTypeConcDil combining information about the formulation type
and the concentration status appears in all models in Table B.4 and is an important variable for
predicting dermal absorption. Other variables, for example exposure duration and skin type, might be
seen as playing an important role. However, the improvement in DIC value when these variables are
included, or even when all 11 variables are included, is modest compared to the improvement when
active substance code is included in the second model in Table B.3. This is evidence of confounding
between active substance code and other variables and this confounding is discussed further in
Section 3.2 of Appendix B.
k (number of
explanatory
variables)
Best submodel DIC
13 logMW + logPow + WaterSolub + FormTypeConcDil + logMolConc + SkinType +
Age + Sex + Duration + ChamberType + ReceptMedium + AScode + Recovery
25,946.93
FormTypeConcDil is the ﬁve level categorical variable combining formulation type and concentration status deﬁned above,
logMolConc = ‘log molar concentration’, AScode = ‘active substance code’, ReceptMedium = ‘receptor medium’, Duration =
‘exposure duration’, SkinType = ‘skin type’, WaterSolub = ‘water solubility’, ChamberType = ‘chamber type’, logMW = ‘logarithm of
molecular weight’, Recovery = ‘mass balance recovery’, logPow = ‘logarithm of Pow’.
Table B.4: List of best k–variable, excluding active substance code and receptor medium, models in
terms of Deviance Information Criterion. For the meaning of abbreviations, see the
caption to Table B.3.
k (number
of explanatory
variables)
Best submodel without AScode and Receptor Medium DIC
1 FormTypeConcDil 22,021.54
2 FormTypeConcDil + Duration 22,327.99
3 FormTypeConcDil + SkinType + Duration 22,435.64
4 FormTypeConcDil + SkinType + Age + Duration 22,534.35
5 FormTypeConcDil + logMolConc + SkinType + Age + Duration 22,616.08
6 logMW + logPow + FormTypeConcDil + logMolConc + SkinType + Duration 22,662.22
7 logMW + logPow + FormTypeConcDil + logMolConc + SkinType + Age + Duration 22,769.96
8 logMW + logPow + FormTypeConcDil + logMolConc + SkinType +
Age + Duration + ChamberType
22,791.25
9 logMW + logPow + WaterSolub + FormTypeConcDil + logMolConc + SkinType +
Age + Duration + ChamberType
22,802.63
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Diagnostic analysis suggested that the Beta regression models provide a ﬁt of modest quality.
Consequently, no further use was made of Beta regression models in arriving at the recommendations
for default values provided in Section 5 of Appendix B. However, the knowledge gained from the
modelling as described above helped to deﬁne the categories used for deﬁning default values.
3.2. Logit regression modelling
The logit function transforms values between 0 and 1 to the whole real line. It is widely used in
statistical analysis of proportions and probabilities (e.g. the logistic regression method). Here, the logit
function was applied to the fraction absorbed and the resulting variable was used as the response for
standard regression modelling. As described in Section 1 of Appendix B, the logit transformation
applied to the fraction absorbed provides a variable that is less skewed and for which variability is
more homogeneous. However, approximately 2% of the records in the data set (ECPA + BfR) have
zero absorption and they would be have to be excluded if the logit transformation was not adapted.
For this reason, all fraction-absorbed values were ‘shrunk’ slightly towards 0.5 by ﬁrst calculating
0.5 + 0.9995 (x  0.5) before applying the logit transformation. The shrinkage constant 0.9995 was
arrived at by experimenting to ﬁnd a number that makes the zero absorption cases ﬁt naturally on the
tail of the distribution of resulting logit values.
The range of models considered was inﬂuenced by the results of the beta regression modelling in
Section 3.1 of Appendix B and a smaller range of models was explored. The conclusions were
essentially the same: of the physicochemical, formulation category, skin and experimental condition
variables, only concentration status (concentrate/dilution) and the formulation grouping into categories
were found to explain a substantial amount of variation of absorption.
Figure B.4 shows the dependence of fraction absorbed on concentration, using a logit scale for
fraction absorbed and a logarithmic scale for concentration. There is a clear difference between
dilutions and concentrates and any further dependence on concentration is weak. There is overlap in
terms of concentration between the dilutions and concentrates and this precludes establishing a
concentration threshold to distinguish dilutions from concentrates. Figure B.5 shows, separately for
dilutions and concentrates, the dependence of fraction absorbed on the formulation category.
k (number
of explanatory
variables)
Best submodel without AScode and Receptor Medium DIC
10 logMW + logPow + WaterSolub + FormTypeConcDil + logMolConc + SkinType +
Age + Duration + ChamberType + Recovery
22,801.07
11 logMW + logPow + WaterSolub + FormTypeConcDil + logMolConc + SkinType +
Age + Sex + Duration + ChamberType + Recovery
22,797.15
Figure B.4: Dependence of fraction absorbed (logit scale) on concentration (logarithmic scale)
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An important tool in standard regression modelling (e.g. Draper and Smith, 1998) is sequential
analysis of variance which tries to show how much explanatory variables account for variation in the
response. Several analyses of variance were carried out to establish as far as possible the sequence of
sources of variation which best accounts for variation of the response. The preferred analysis ﬁrst
includes the formulation category and concentration status (dilution/concentrate) variables and then
adds in turn:
• the active substance categorical variable and per-substance difference between dilution and
concentrate;
• the study identiﬁer and within-study variation between different concentrations and detailed
formulations for the same substance;
• donor id within study.
Other analyses not presented in detail here considered the role of explanatory variables identiﬁed
as potentially important in Tables B.3 and B.4: exposure duration, receptor medium and skin type. A
categorical variable indicating the data source (ECPA or BfR) from which a measurement came was
also considered. It was found that while each of these variables could explain a substantial amount of
variation if included in the model prior to the active substance variable, it explained relatively little
variation if included after the active substance variable. This is evidence of substantial confounding
between these other variables and the active substance variable. Since none of these other variables is
a property of the active substance or of its formulation they were omitted from subsequent modelling.
As a result, variation which is explained by them, but not by active substance code, is effectively
included in the variation explained by terms included in the second bullet above.
3.2.1. Results
The results are shown in Tables B.5 and B.6. Table B.5 uses the full data set (ECPA + BfR) and
therefore omits donor id. Table B.6 is based on those records in which donor id was recorded. Despite
being based on a subset of the data, it reaches very similar conclusions about the proportions of
variance explained by the various sources and provides additional information about the decomposition
of replication variation into between- and within-donor components.
On the basis of Table B.5, a random-effects multiple regression model (e.g. Pinheiro and Bates,
2002) was ﬁtted, taking the logit of (shrunk) fraction-absorbed as the response variable and estimating
ﬁxed effects for the formulation category and concentrate/dilution and random effects for each of the
other sources of variation in Table B.5. The model was ﬁtted in R (R Core Team, 2016) using the
Bayesian MCMCglmm package (Hadﬁeld, 2010) and the results checked for consistency with more
traditional restricted maximum likelihood ﬁtting using the lme4 package (Bates et al., 2015). An
advantage of the Bayesian approach is that uncertainty about parameter estimates is easily accessed
and used to obtain uncertainty about quantities derived from the parameters (see Section 5.2 of
Appendix B).
Figure B.5: Dependence of fraction absorbed (logit scale) on formulation category and on
concentration status (dilution/concentrate)
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4. The role of Pow and MW
The EFSA PPR Panel guidance on dermal absorption issued in 2012 states that if log Pow < 1 or
> 4 and MW > 500 a default dermal absorption value of 10% may be applied (EFSA PPR Panel, 2012)
but does not provide detailed reasoning to support the default value. This focusses attention on how
absorption depends on MW and Pow.
Pow and MW are continuous quantitative variables and there is no well identiﬁed knowledge
supporting the idea that the biochemical process of dermal absorption undergoes a transition beyond
the cut-off log Pow < 1 or > 4 and MW > 500, with speciﬁc consequences for dermal absorption
values. Therefore, for the statistical modelling, Pow and MW were treated as continuous variables
having potentially a continuous effect on dermal absorption.
Figure B.6 shows the relation between fraction absorbed and log Pow. Figure B.7 shows the relation
between fraction absorbed and MW. Neither ﬁgure shows any strong indication of a predictive
relationship. A similar lack of a strong relationship was found when ﬁgures were produced separately
for each combination of formulation category and concentration status. This kind of graphical
investigation could be misleading due to possible confounding effects. However, the ﬁnding is
consistent with the statistical modelling results which did not show a big role for either explanatory
variable.
For records in this category, median and mean fraction absorbed are, respectively, 3.1% and 5.7%.
The 75th, 95th and 99th percentiles are 18%, 31% and 34%. These are not strikingly different from
summaries for the whole data set, especially given that the distribution of formulation category and
concentration status is not the same.
Therefore, no speciﬁc default values are proposed in Section 5 of Appendix B and Section 6.1 for
this category of active substances.
Table B.6: Sequential analysis for the reduced data set consisting of records which include donor id
Source block Source of variation
Degrees of
freedom
Sum of
squares
Mean square % variation
1 Dilution/concentrate 1 7,848 7,848 32
Formulation category 3 836 279 3
2 Active substance 205 6,741 33 28
Active substance speciﬁc
dilution/concentrate
183 1,732 9.5 7
3 Study 162 2,137 13 9
Concentrations and formulations
for same active substance
within study
307 1,325 4.3 5
4 Replicates: between donors 2362 2,472 1.0 10
Replicates: within donor 2602 1,252 0.5 5
Table B.5: Sequential analysis of variance for the full data set (ECPA + BfR)
Source block Source of variation
Degrees of
freedom
Sum of
squares
Mean
square
% variation
1 Dilution/concentrate 1 9,119 9,119 33
Formulation category 3 849 283 3
2 Active substance 233 7,813 34 28
Active substance speciﬁc
dilution/concentrate
213 2,097 9.8 7
3 Study 194 2,422 12 9
Concentrations and formulations
for same active substance within study
342 1,526 4.5 5
4 Replicates 5778 4,153 0.72 15
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5. Calculations intended to support setting of default values
Two approaches are provided to calculations intended to support setting of default values: empirical
percentiles and model-based percentiles. Results are presented for: eight categories based on four
formulation categories and distinguishing dilutions from concentrate products, and four categories
based on combining the formulation categories to make two groups and again distinguishing dilutions
from concentrate products.
5.1. Empirical percentiles
Empirical percentiles are shown in Tables B.7 and B.8. The values shown are for the 95th, 97.5th
and 99th percentiles. Because the values shown are estimates obtained from a particular data set,
they are subject to uncertainty. Therefore, the upper bound of a one-sided ≥ 95% conﬁdence interval
is also shown for each estimated percentile. The conﬁdence interval calculation is based on the
assumption that the data are a random sample from a homogeneous population. This assumption
does not hold here but the conﬁdence limit is shown anyway, in order to provide some indication of
what the level uncertainty might be.
The conﬁdence interval calculation used is a well known statistical method and is described and
justiﬁed by, for example, Hollander and Wolfe (1999). Let n be the sample size for a random sample
from a continuous distribution. The principle is that the upper conﬁdence limit is the rth order statistic
(rth value in sample sorted in increasing numerical order) where r is the smallest whole number such
that the probability that a binomial random variable, with n trials and probability a of success in each
trial, produces a value less than r is at least the desired conﬁdence level.
Figure B.6: Scatter plot of dermal absorption vs log Pow. Vertical green lines depict cut off at log
Pow < 1 and > 4. Horizontal black line depicts the 10% value. Red crosses denote
records for which log Pow < 1 or > 4 and MW > 500
Figure B.7: Scatter plot of dermal absorption vs molecular weight. Vertical green line depicts cut off
at MW > 500. Horizontal black line depicts the 10% value. Red crosses denote records
for which log Pow < 1 or > 4 and MW > 500
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5.2. Model based
The random effects logit regression model described in Section 3.2 of Appendix B was used to
make calculations to support setting of default values.
The model includes random effects for active substances (and related variables). This means that
the effects for active substances are modelled as being sampled from a normal distribution. The
parameters of that distribution are among those estimated from the data when ﬁtting the model. The
unknown effect for a new substance can be seen as a draw from that distribution and this quantiﬁes
uncertainty about absorption for the new substance. The same approach can be taken for each
random effect in the model and so it becomes important to decide which sources of variation should
be addressed/covered by the default value.
Source block 1 in Tables B.5 and B.6 deﬁnes the eight categories described at the start of Section 5
in Appendix B. Source block 2 relates directly to variation between active substances and the default
value should address this. Source block 4 (replicate variation) is driven by inter- and intrahuman
variability and by intralaboratory variation and therefore need not be addressed by the default value.
That leaves source block 3 for which there is a decision to be taken between three possibilities for
addressing the variation contained in it: (a) exclude it altogether, (b) include only the between-study
variation, (c) include both sources in block 3 (between- and within-study variation).
Table B.7: Empirical estimates of percentiles, with upper conﬁdence limits, for three percentiles of
variability and four formulation categories
Formulation
category
Dilution/
concentrate
Sample
size
Quantile
95%
Upper
bound
95%
CI
Quantile
97.5%
Upper
bound
95%
CI
Quantile
99%
Upper
bound
95%
CI
Organic
solvent
Concentrate 1,153 18 20 24 30 32 44
Water based Concentrate 1,073 8 10 16 21 28 41
Solid Concentrate 471 8 11 11 14 14 17
Other Concentrate 131 20 NA 65 NA 84 NA
Organic
solvent
Dilution 1,553 49 55 64 67 73 80
Water based Dilution 1,567 40 44 55 60 69 75
Solid Dilution 710 51 57 63 72 74 102
Other Dilution 105 56 61 58 NA 61 NA
CI: conﬁdence interval; NA: situations in which there was insufﬁcient data to obtain an upper conﬁdence limit.
Table B.8: Empirical estimates of percentiles, with upper conﬁdence limits, for three percentiles of
variability and two formulation categories
Formulation
category
Dilution/
concentrate
Sample
size
Quantile
95%
Upper
bound
95%
CI
Quantile
97.5%
Upper
bound
95%
CI
Quantile
99%
Upper
bound
95%
CI
Organic
solvent +
other
Concentrate 1,284 18 20 25 31 35 50
Water based +
solid
Concentrate 1,544 8 9 13 16 24 33
Organic
solvent +
other
Dilution 1,658 51 55 62 67 73 80
Water based +
solid
Dilution 2,277 45 48 57 61 70 74
CI: conﬁdence interval.
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Having decided which random effects sources should be covered by the calculated values, there are
two further decisions to be made. The ﬁrst is what percentile of the random variation is of interest; if
only source block 2 is included in the calculation, this is equivalent to asking what percentage of active
substances should be covered by the calculated value. The calculated value can then be determined
from the parameter estimates for the random effects model. However, there is uncertainty about the
parameters as they are estimated from data and so the second decision is how to address that
uncertainty, for example by taking a central estimate or by considering an upper credible limit.
Table B.9 shows calculated values based on the 95th percentile of random effects variation for each
of the eight categories. In each category, values are shown for each of options (a), (b) and (c) and
uncertainty is addressed by showing the central estimate of the default value and the upper 95th
percentile of uncertainty about the default value. Tables B.11 and B.13 show results for the 97.5th and
99th percentiles. Tables B.10, B.12 and B.14 show the corresponding results for four categories.
Table B.9: Values calculated from random effects logit regression model to support setting default
values based on the 95th percentile of variability for formulations in four categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent Concentrate 5 7 8 10 11 14
Water based Concentrate 3 4 4 6 6 8
Solid Concentrate 3 4 4 6 6 8
Other Concentrate 3 6 5 8 7 11
Organic solvent Dilution 37 45 48 56 57 64
Water based Dilution 24 30 33 39 41 47
Solid Dilution 24 30 33 39 41 48
Other Dilution 27 39 37 49 46 58
Upper 95th percentile values are presented in italics.
Table B.10: Values calculated from random effects logit regression model to support setting default
values based on the 95th percentile of variability for formulations in two categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent + other Concentrate 5 7 8 10 11 13
Water based + solid Concentrate 3 4 4 6 6 8
Organic solvent + other Dilution 36 44 47 54 56 62
Water based + solid Dilution 23 29 32 38 40 46
Upper 95th percentile values are presented in italics.
Table B.11: Values calculated from random effects logit regression model to support setting default
values based on the 97.5th percentile of variability for formulations in four categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent Concentrate 7 10 11 15 16 20
Water based Concentrate 4 5 6 8 9 12
Solid Concentrate 4 6 6 9 9 12
Other Concentrate 4 7 7 12 11 17
Organic solvent Dilution 45 54 58 66 68 74
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Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Water based Dilution 29 37 41 49 52 59
Solid Dilution 29 38 42 50 52 59
Other Dilution 34 46 46 59 57 69
Upper 95th percentile values are presented in italics.
Table B.12: Values calculated from random effects logit regression model to support setting default
values based on the 97.5th percentile of variability for formulations in two categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent + other Concentrate 7 9 11 14 16 20
Water based + solid Concentrate 4 5 6 8 9 12
Organic solvent + other Dilution 43 52 56 64 66 72
Water based + solid Dilution 29 36 41 48 52 58
Upper 95th percentile values are presented in italics.
Table B.13: Values calculated from random effects logit regression model to support setting default
values based on the 99th percentile of variability for formulations in four categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent Concentrate 10 14 17 22 25 31
Water based Concentrate 5 8 9 13 15 19
Solid Concentrate 5 8 9 13 15 20
Other Concentrate 6 10 11 17 17 26
Organic solvent Dilution 53 63 68 75 78 83
Water based Dilution 37 47 53 61 65 71
Solid Dilution 37 47 53 61 65 72
Other Dilution 42 55 58 69 69 79
Upper 95th percentile values are presented in italics.
Table B.14: Values calculated from random effects logit regression model to support setting default
values based on the 99th percentile of variability for formulations in two categories
Formulation category Dilution/concentrate
Options for sources of variation from source
block 3 to be covered by the default value
(a) None
(b) Between-
study only
(c) All
Organic solvent + other Concentrate 9 13 16 21 24 30
Water based + solid Concentrate 5 8 9 13 15 19
Organic solvent + other Dilution 51 61 67 74 77 82
Water based + solid Dilution 36 46 52 60 64 70
Upper 95th percentile values are presented in italics.
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5.3. Advantages and disadvantages of the two different approaches
The empirical approach has the merit that it is easily understood and is relatively easy to
implement. However, it has some weaknesses:
• when a particular percentile of variability is chosen, it includes all sources of variability
including inter- and intra-human and intra-laboratory which should really be excluded;
• it gives equal weight to each record in the data set and takes no account of the fact that there
are more studies (and a wider variety of experimental conditions) for some substances than
others, and a varying number of replicates;
• the method used to assess uncertainty about the chosen percentile is designed for a random
sample from a homogeneous population rather than for a hierarchically structured data set.
The modelling approach addresses all the weaknesses identiﬁed for the empirical approach but has
potential weaknesses of its own:
• there is always some doubt about the selection of particular statistical model and no evaluation
has been made of alternative models;
• in particular, the model assumes that random effects are homogeneous across the 8 (or 4)
categories, whereas the empirical approach treats each category separately;
• the model makes distributional assumptions which may not be valid: random effects and
replicate variation are both assumed to be normally distributed.
Some identiﬁed weaknesses of the modelling approach could be addressed by further statistical
analysis, whereas the weaknesses of the empirical approach are difﬁcult to overcome. Possible
enhancements to the statistical model include relaxation of various normal distribution assumptions,
introduction of heterogeneity between the categories and the incorporation of additional predictive
physicochemical properties.
Both approaches assume that the substances and the formulations in the data set (ECPA + BfR) are
fully representative for products and their in-use dilutions to which default values would in future be
applied. As the latter cannot be predicted, it was considered technically not feasible to perform a
corresponding analysis of representativeness/coverage of the relevant chemical space.
6. Proposals for overall default values
The data were analysed by two different approaches as (see Section 5 in Appendix B):
1) The percentage upper conﬁdence level/credibility limit of a percentile of the empirical
absorption data;
2) Random effects logit regression modelling.
Each approach has their merits and drawbacks as discussed and it was not possible to conclude
which performed best.
Therefore, the proposals below are based on an integrating the outcomes of the two approaches
and also taking into account the previous default values and the adaptations of the default values
reported in the PPR Panel guidance issued in 2012 (EFSA PPR Panel, 2012) are proposed as speciﬁed
in Table B.15.
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These proposals are pragmatic and represent a reasonable worst case that takes into account the
95% upper conﬁdence/credibility limit of the 95th percentile of the respective empirical relative
absorption data for the different formulations and of the relative absorption data predicted using
random effects logit regression modelling, as well as the remaining uncertainties relating to the
representativeness of the data set (ECPA + BfR). They are speciﬁed by formulation category and
concentration status (‘concentrate’ or ‘dilution’) as the statistical analyses performed on the EFSA
pesticide data set (ECPA + BfR) indicated that these parameters were the main drivers of variation in
the absorption data.
The default value for diluted organic-based product is proposed to be 70%, constituting an overall
value covering the upper conﬁdence/credibility limits of both analyses. This value is also proposed for
the dilutions of ‘other formulations’, since the results obtained from the statistical analyses performed
do not justify deviation from the highest default of 70% established in the PPR Panel guidance (EFSA
PPR Panel, 2012) in view of the scarcity of the data available for this heterogeneous category.
For solids and water-based products, both concentrated and diluted, default values can be
substantially revised based on the new data set (ECPA + BfR). Values of 10% and 50%, for
concentrated and diluted product, respectively, are proposed, reﬂecting the outcomes of both analyses
carried out.
The default value for the organic-based formulations is proposed to be maintained at 25% for
concentrated products, since the analysis of the new data set does not suggest a substantially
different value. With regard to the category ‘other formulations’, new data were scarce and members
of the category very diverse, which was considered no robust basis to suggest a revision of the default
value.
It follows that if more data become available, especially for the formulation category ‘other’,
revision of default values and categorisation could be considered.
Table B.15: Default values to be used in the absence of experimental data
Formulation category Concentration status Default value (%)
Organic solvent-based(a) and others(b) Concentrate 25
Dilution 70
Water-based/dispersed(c) or solid(d) Concentrate 10
Dilution 50
(a): Emulsiﬁable concentrate (EC), emulsion, oil in water (EW), suspo-emulsion (SE), dispersible concentrate (DC), oil miscible
liquids (OL/OF), oil-based suspension concentrates (OD), emulsion for seed treatment (ES), microemulsion (ME).
(b): Bait concentrate (CB), capsule suspension (CS), gel for direct application (GEL/GD), bait, ready for use (RB), mixture of
capsule suspension and suspension concentrate (ZC), seed coated with a pesticide (PS), experimental solution of active
substances in solvent (AI).
(c): Soluble concentrate (SL), suspension concentrate (SC), ﬂowable concentrate for seed treatment (FS), ﬂowable (FL) (=SC).
(d): Wettable powder (WP), water-dispersible granules (WG/WDG), water-soluble granules (SG), water-soluble powder (SP),
powder for dry seed treatment (DS).
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Appendix C – Evaluation of dermal absorption guidance/guideline
documents
1. Data and methodology
The evaluation of available documents on dermal absorption was performed in order to identify
potential inconsistencies/discrepancies among them on the same factor/criterion covering both
experimental and data analysis aspects. Moreover, identiﬁed reference documents were also screened
to collect different level of details provided for the same factor/criterion.
Information on the conduction and interpretation of dermal absorption experiments for chemicals
described in OECD Test Guideline (TG) 428 (2004b), OECD guidance 28 (2004c) and OECD guidance
notes on dermal absorption (2011) were evaluated against EFSA PPR Panel guidance on dermal
absorption (EFSA PPR Panel, 2012) developed for PPPs, and the EFSA opinion on the ‘Science behind
the revision of the guidance document on dermal absorption’ (EFSA PPR Panel, 2011). Other general
guidance documents on dermal absorption (Hoang, 1992; WHO, 2006; ECETOC, 2013) as well as
guidance developed for speciﬁc products such as cosmetics (SCCS, 2010, 2015) and medicines (EMA,
2014) were included in the analysis.35 Deviations from OECD and EFSA dermal absorption documents
when performing the study were collected during the quality check of new submitted human in vitro
experiments, described in the EFSA Scientiﬁc Report ‘Assessment of new scientiﬁc studies on human
in vitro dermal absorption’ (EFSA, 2015).
Critical information on the conduction and the assessment of human in vitro dermal absorption
studies were grouped into categories and evaluated through the documents accordingly:
i) experimental aspects, such as: study design, skin origin/region/type/preparation, sampling
period, washing procedure, tape stripping, etc.; factors possibly inﬂuencing dermal absorption,
such as humidity, temperature, state of occlusion, skin site, skin irritation, etc.;
ii) data analysis, such as: recommendations to account for experimental variability, to identify
outliers, to calculate t0.5, criteria for recovery acceptability, recommended default values
(DVs), etc.
2. Results
The evaluation of collected information from the selected dermal absorption documents covering
the same factor/criterion evidenced the following deviances/discrepancies:
i) Experimental variability (intra-assay):
• EFSA (EFSA PPR Panel, 2012), like SCCS (2010, 2015), recommends the use of eight skin
samples from at least four donors for a reliable dermal absorption study. A minimum of
four replicates36 per test preparation is requested by OECD TG 428 (2004b). EMA (2014)
recommends to use a sufﬁcient number of replicates (the choice should be demonstrated
to be statistically signiﬁcant), typically six or more for pivotal experiments, and at least two
different donors.
• From analysis of submitted study reports, the EFSA/SCCS recommendation to reduce
experimental variation, which was based on practical experience with the type of study, is
not followed as only the OECD minimum requirement (four replicates, irrespective of the
donors) is often applied.
• No instructions are provided by any of the screened documents on criteria to be applied
for the identiﬁcation of outliers. For both EFSA (EFSA PPR Panel, 2012) and OECD (2011),
the reason for excluding outliers should be clearly stated in the study report (and in the
summary text for EFSA). Moreover, the full results from samples considered to be outliers
must be presented and results treated as outliers should include spuriously low as well as
high values. However, from the check of submitted study reports these recommendations
are not routinely followed.
35 WHO/ECETOC/EPA documents were screened to collect different level of details provided for the same factor/criterion.
36 EFSA (2012): If results from four replicates are not available, it is possible to use the mean value of three replicates if the
results are closely matched or, if there is signiﬁcant variation, take the highest value rather than the mean.
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• EFSA (EFSA PPR Panel, 2012)37 and OECD (2011) approach for high variability within
replicates (i.e. standard deviation is equal or larger than 25% of the mean of the
absorption as deﬁned in Section 5.6 and 5.8) to add a standard deviation to the mean
value is not followed by ECPA (Aggarwal et al., 2014, 2015), as evidenced from the quality
check of submitted study reports. For cosmetics (SCCS, 2015), a standard deviation should
be added to the mean value by default (two standard deviations in case of deviations from
protocol and/or very high variability).
ii) Data analysis:
• Recovery acceptability criteria: OECD TG 428 (2004b) requires mean mass balance
recovery of the test substance between 90% and 110% (100  10%). The same
recommendation is expressed in OECD guidance document 28 (2004c) plus, under certain
circumstances, such as for a volatile substance, a range of 80–120% (100  20%) is
acceptable. EFSA (EFSA PPR Panel, 2012) requirement for recovery is 95–105%, whereas
the SCCS (2015) criterion is less stringent (85–115%). The EFSA range for acceptable
recovery (including normalisation when recovery is outside the range) is not applied by
ECPA (Aggarwal et al., 2014, 2015) and from the evaluation of submitted studies; it was
that 96.4% records met the OECD criterion. EMA guidance (2014) provides the same
recommendation as OECD TG 428 (2004b).
• Default values: OECD (2011) and EFSA (EFSA PPR Panel, 2011, 2012) both recommend to
use, in the absence of experimental data, a default of 10% for substances with MW > 500
and log Pow < 1 or > 4. Additional default values of 25% and 75% are recommended by
EFSA38 (2011; 2012) for products containing > 5% active substance and for products or
in-use dilutions containing ≤ 5% active substance, respectively. OECD (2011) assumes that
as a ﬁrst step, a default value of 100% should be used in exposure calculation, to cover a
worst-case scenario. For cosmetics (SCCS, 2015), default values of 10% (as OECD) and
50% are recommended.
• t0.5 calculation: EFSA’s (EFSA PPR Panel, 2011, 2012) recommendation for the exclusion of
tape strips from the dermal absorption calculation is based on the calculation of t0.5, i.e.
the ‘total absorption (material in the receptor ﬂuid at the end of the study) occurred within
half duration of the total sampling period’. From evaluation of submitted study reports, it
was found that, based on EFSA’s deﬁnition of t0.5, at least three different approaches
were applied to calculate t0.5, leading to different results. The same approach is
recommended by the OECD guidance notes 156 (2011). However, none of the documents
provides detailed guidance on the calculation of the value, which in practice has resulted in
diverging assessments of the same data. Also, this approach has been criticised for not
making adequate use of the data generated at many different time points as it is required
by the OECD TG 428 (2004b).
• Pro-rata/Bridging: EFSA (EFSA PPR Panel, 2011, 2012) recommends a ‘pro rata approach’
to extrapolating dermal absorption values from tested dilutions to non-tested dilutions of
the same concentrate (for PPPs). For bridging of studies on dermal absorption performed
with tested formulations to non-tested formulations, EFSA (EFSA PPR Panel, 2012) deﬁnes
criteria for similarity of formulations.
3. Conclusions
The evaluation of existing documents on dermal absorption has identiﬁed diverging
recommendations to reduce experimental variability, recovery acceptability criteria and default values
to be used in the absence of experimental data. This analysis clearly indicates the need for improved
harmonisation among guidance/guideline documents on dermal absorption. In addition, from the
quality check of the submitted study reports, it was noted that some recommendations are not
routinely followed when performing, analysing and reporting studies. In some cases, even when an
aspect is covered in a single document, the need for clarifying the recommendations was identiﬁed
(t0.5 calculation, now clariﬁed in Section 5.1). Although studies are, in general, in line with
requirements in OECD TG 428 (OECD 2004b), this document provides only few details on experimental
37 A revised approach for the treatment of variability within the results is provided in the current guidance (see Section 5.3).
38 New default values are reported in the current guidance, revised on the basis of the analysis of new human in vitro dermal
absorption data (see Section 6.1, ﬂow chart 1a and Appendix B).
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conduct, and data analysis and reporting recommendations are not included, as covered in guidance
documents (OECD, 2011; EFSA PPR Panel, 2012).
In the absence of data, several approaches are currently used by different competent authorities as
well as different applicants. Thus, deﬁned rules are needed to harmonise mutual regulatory acceptance
of assessments generated across different regulatory purposes.
It is therefore recommended to revise the OECD dermal absorption guidance, guidance document
and test guideline documents in order to support a more harmonised approach for the evaluation of
dermal absorption of chemicals, reﬂect more appropriately the extensive experience gained using the
in vitro methods, and to increase global acceptance of this method as a replacement for testing in
animals.
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Appendix D – Evaluation of literature on QSAR for skin absorption
prediction
1. QSARs
Typically, QSARs are based on training sets derived from in vitro dermal absorption experiments.
Most QSARs developed to predict skin permeation of chemicals target the permeation constant (kp),
and a few maximum ﬂux (Jmax) (Mitragotri et al., 2011). Occasionally, also QSARs for percentage
absorption have been developed (e.g. by Gute et al., 1999), but although preferred from a regulatory
point of view, they have limited value, since this parameter is highly inﬂuenced by exposure conditions
such as duration and dermal loading.
Many algorithms of global QSARs for aqueous solutions have been reviewed in the publically
available literature (Buist, 2016). The majority of these QSARs relate permeation to the octanol–water
partition coefﬁcient (KOW) and molecular weight (MW). When tested, log KOW and MW-based QSARs
did not provide good predictions with external validation sets (R2 for the correlation between observed
and predicted values <0.5). Also, QSARs using molecular descriptors other than log KOW and MW did
not perform well with external validation sets. A possible explanation for the bad performance of these
QSARs may be that they are mainly derived by multiple linear regression, whereas the relation
between kp or Jmax and at least some of the descriptors used is not always linear.
New developments in QSAR development include neural network, nearest neighbour and Gaussian
process models (Buist, 2016). These novel models predict non-linear processes, and Gaussian process
models have been shown to perform better than selected QSARs, as have fuzzy models and artiﬁcial
neural networks. However, they yet have to prove their practical value, e.g. when tested with external
validation sets.
Little work has been done to include vehicle effects in QSAR predictions, most of which include a
mixture factor, a composite descriptor (Buist, 2016). Each of these QSARs were based on a small
training set of less than 20 molecules, and all showed quite different mixture factors.
2. Mathematical skin models
The QSARs described in the previous section merely predict a constant (kp or Jmax) of the skin
permeation process. In order to calculate actual amounts of permeant crossing the skin under relevant
exposure conditions, a mathematical skin model is needed. The simplest model only considers the
stratum corneum, being the major barrier for dermal absorption in most cases, and regards it as
homogeneous compartment (see Russell and Guy, 2009; Mitragotri et al., 2011; Anissimov et al.,
2013). Also, more complex models of the skin mainly concern the stratum corneum. Most of them
describe the structure of the stratum corneum more accurately as a so called ‘brick-and-mortar’ model
(Mitragotri et al., 2011; Anissimov et al., 2013). Although receiving less attention, viable epidermis and
avascular and vascular dermis have been modelled as well (Anissimov et al., 2013). Every
compartment added to the skin model implies an increase in parameters to describe partitioning
between the different compartments and diffusion across them, and increases the mathematical
complexity of the models and thereby the data needs of the models in order determine the various
chemical-speciﬁc and skin speciﬁc parameters (Mitragotri et al., 2011; Anissimov et al., 2013). This
means that, in general, the usability of the more complex models in regulatory risk assessment will be
limited, due to lack of data to populate the models with the necessary parameters. Furthermore,
specialist numerical skills are required to use complex models (Anissimov et al., 2013). The latter
objection is mitigated by a versatile and complex skin model, the Finite Dose Skin Permeation Model
(FDSP) made available on the Internet39 by the US Centers for Disease Control and Prevention (CDC).
Unfortunately, it did not perform well with an external validation data set (Buist, 2016).
Mathematical skin models need the input chemical-speciﬁc parameters like kp, however, as
explained above, no reliable method to predict kp is currently available (Buist et al., 2010; Buist, 2016).
3. Recommendations
In future, the current QSARs for kp could be replaced by models with better predictive qualities to
be used with selected mathematical skin models to predict dermal absorption, as deﬁned in this
guidance (as the sum of the relative amount permeated into the receptor ﬂuid and the relative amount
39 http://www.cdc.gov/niosh/topics/skin/ﬁniteSkinPermCalc.html
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still present in the skin (minus the ﬁrst two tape strips)). Besides log KOW and MW, the physicochemical
parameters that are used in most of the dermal absorption QSARs, an additional predictive
independent variable is needed which describes the chemical reactivity of the substance, e.g. hydrogen
bonding. Furthermore, the kp model to be developed should be non-linear with respect to the
relationships between kp and the predictive independent variables, since non-linear models seem to
outperform the traditionally developed linear models. A disadvantage of non-linear models is that more
data are needed to develop them than for linear models, and that they are more prone to overﬁtting.
Therefore, existing dermal absorption data sets, both public and private, could be combined, curated
and ﬁltered to build a large homogeneous and consistent data set that can be used to develop such
non-linear models to predict kp.
Concerning the available models for the estimation of dermal absorption of chemicals, including
mixtures, brieﬂy reviewed in Sections 1 and 2 of Appendix D, it is recommended to evaluate their
applicability to a large and homogenous data set of human in vitro dermal absorption studies with
PPPs, as the data set (ECPA + BfR) described in Appendix A. An extensive review of all the available
models including a critical appraisal based on OECD criteria (OECD, 2007) should be conducted to
select models to be used for testing their predictability and reliability of predictions of dermal
absorption for pesticides.
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